

ประวัติคณะผู้วิจัย

หัวหน้าโครงการ

(ภาษาไทย) นายแพทย์เกียรติ รักษ์รุ่งธรรม

ตำแหน่งทางวิชาการ ศาสตราจารย์

(ภาษาอังกฤษ) Prof. Kiat Ruxrungtham, M.D.

ภาควิชา สาขาวิชาโรคภูมิแพ้และภูมิคุ้มกัน ภาควิชาอายุศาสตร์ คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย

โทรศัพท์ 0-2256-4152

โทรสาร 0-2254-2323

E-mail rkiat@chula.ac.th

หน่วยงานและสถานที่ที่ติดต่อได้ สาขาวิชาโรคภูมิแพ้และภูมิคุ้มกัน ภาควิชาอายุศาสตร์ คณะแพทยศาสตร์

จุฬาลงกรณ์มหาวิทยาลัย เลขที่ 1873 ถ.พระราม 4 แขวงวังใหม่ เขตปทุมวัน กรุงเทพฯ 10330

โทรศัพท์ 086-335-4655

ประวัติการศึกษา

สถาบันการศึกษา	ระดับการศึกษา	ปีที่จบการศึกษา	สาขา
คณะแพทยศาสตร์ มหาวิทยาลัยเชียงใหม่, ไทย	ปริญญาตรี ด้านการแพทย์ (เกียรตินิยมอันดับหนึ่ง)	2522	ปริญญาบัตร แพทยศาสตรบัณฑิต
คณะแพทยศาสตร์ มหาวิทยาลัยเชียงใหม่, ไทย	แพทย์ประจำบ้าน	2523-2526	แพทยศาสตรบัณฑิต
หน่วยโรคภูมิแพ้และภูมิคุ้มกันทางคลินิก คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย, ไทย	แพทย์ประจำบ้านต่อ ยอดด้านภูมิแพ้และภูมิคุ้มกัน	2524-2526	ภูมิแพ้และภูมิคุ้มกัน
ภาควิชาอายุศาสตร์ คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย, ไทย	ปริญญาโท	2531-2532	ภูมิแพ้และภูมิคุ้มกัน
Johns Hopkins Hospital, Baltimore, Maryland, USA. Sponsored by U.S. AID Supervisor: Thomas C. Quinn, MD.	Guest Research on AIDS	2531-2533	วิจัยด้านโรคเอดส์
San Francisco General Hospital and University of California, San Francisco, California, USA. Supervisor: Sharon Safrin, MD	World AIDS Foundation Intensive Tutorial in AIDS-related Clinical Trials	2531-2534	วิจัยทางคลินิกด้านโรคเอดส์

Laboratory of Immunoregulation (LIR) National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH) Bethesda, Maryland, USA. Supervisor: H. Clifford Lane, MD.	Visiting Researcher	2534-2536	ห้องปฏิบัติการ ภูมิคุ้มกันวิทยาทาง คลินิก
---	---------------------	-----------	---

ความชำนาญ/ความสนใจพิเศษ: โรคเอดส์, โรคภูมิแพ้ และการพัฒนาวัคซีน
ประสบการณ์ที่เกี่ยวข้องกับการบริหารงานวิจัยทั้งภายในและภายนอกประเทศ
งานวิจัยที่ทำเสร็จแล้ว

1. ผู้ร่วมวิจัย: Strategies for Management of AntiRetroviral Therapy (SMART)”

ระยะเวลา: ปี พ.ศ.2544-2550

แหล่งทุน: สถาบันวิจัยสุขภาพแห่งชาติ ประเทศสหรัฐอเมริกา

2. ผู้ร่วมวิจัย: Australian-Thai HIV Vaccine Consortium: pHIS-HIV-A/E (DNA) prime,
rFowlpox-HIV-A/E boost Phase 1 in Thailand

ระยะเวลา: ปี พ.ศ.2549-2550

แหล่งทุน: สถาบันวิจัยสุขภาพแห่งชาติ ประเทศสหรัฐอเมริกา และ the National Centre of HIV
Epidemiology and Clinical Research, Sydney, Australia.

ผลงานวิจัยที่พิมพ์เผยแพร่ จนถึง 18 กค.2553 มี 148 ผลงาน

ตัวอย่างผลงานที่ตีพิมพ์ตั้ง 2547

1. Ruxrungtham K, Pedro RJ, Latiff GH, Conradie F, Domingo P, Lupo S, Pumpradit W, Vingerhoets JH, Peeters M, Peeters I, Kakuda TN, De Smedt G, Woodfall B; TMC125-C227 study group. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. *HIV Med.* 2008; 9:883-96.

2. Ruxrungtham K, Brown T, Phanuphak P. HIV/AIDS in Asia. *Lancet.* 2004; 364 :69-82.

3. Ruxrungtham K, Boyd M, Bellibas SE, Zhang X, Dorr A, Kolis S, Kinchelov T, Buss N, Patel IH. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. *J Clin Pharmacol.* 2004; 44:793-803.

4. Gorowara M, Burger D, Hill A, **Ruxrungtham K**. Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries. *Curr Opin HIV AIDS*. 2010 Jan;5(1):90-6.
5. Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, Santoscoy M, Grinsztejn B, **Ruxrungtham K**, Rimsky LT, Vanveggel S, Boven K; TMC278-C204 Study Group. Efficacy and safety of TMC278 in antiretroviral-naïve HIV-1 patients: week 96 results of a phase IIb randomized trial. *AIDS*. 2010 Jan 2;24(1):55-65.
6. Manosuthi W, Kiertiburanakul S, Amornnimit W, Prasithsirikul W, Thongyen S, Nilkamhang S, **Ruxrungtham K**, Sungkanuparph S. Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure. *AIDS Res Ther*. 2009 Dec 23;6(1):30.
7. van der Lugt J, Lange J, Avihingsanon A, Ananworanich J, Sealoo S, Burger D, Gorowara M, Phanuphak P, **Ruxrungtham K**. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals. *Antivir Ther*. 2009;14(7):1001-4.
8. Puthanakit T, Chokephaibulkit K, Suntarattiwong P, Gorowara M, Leawsrisuk P, Suwanlerk T, Boonrak P, **Ruxrungtham K**. Therapeutic drug monitoring of lopinavir in human immunodeficiency virus-infected children receiving adult tablets. *Pediatr Infect Dis J*. 2010 Jan;29(1):79-82. P
9. Nüesch R, Gayet-Ageron A, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Chautrakarn S, **Ruxrungtham K**, Hirschel B, Anaworanich J; STACCATO study group. The impact of combination antiretroviral therapy and its interruption on anxiety, stress, depression and quality of life in Thai patients. *Open AIDS J*. 2009 Sep 15;3:38-45.
10. Puthanakit T, van der Lugt J, Bunupuradah T, Ananworanich J, Gorowara M, Phasomsap C, Jupimai T, Boonrak P, Pancharoen C, Burger D, **Ruxrungtham K**. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. *J Antimicrob Chemother*. 2009 Nov;64(5):1080-6.
11. Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M, Peeters M, Picchio G, Vingerhoets J, Woodfall B, De Smedt G; DUET-1, DUET-2 study groups. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. *AIDS*. 2009 Nov 13;23(17):2289-300.
12. Bunupuradah T, Suntarattiwong P, Li A, Sirivichayakul S, Pancharoen C, Boonrak P, Puthanakit T, Kerr SJ, **Ruxrungtham K**, Chotpitayasunondh T, Hirschel B, Ananworanich J; the HIV-NAT 013 Study Team. Antiretroviral treatment outcome following genotyping

in Thai children who failed dual nucleoside reverse transcriptase inhibitors. *Int J Infect Dis.* 2009 Aug 20.

13. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. *J Infect Dis.* 2009 Sep 15;200(6):973-83.

14. Manosuthi W, Sungkanuparph S, Tantanathip P, Mankatitham W, Lueangniyomkul A, Thongyen S, Eampokarap B, Uttayamakul S, Suwanvattana P, Kaewsaard S, **Ruxrungtham K**; N2R Study Team. Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfecting patients receiving rifampin. *Antimicrob Agents Chemother.* 2009 Oct;53(10):4545-8.

15. Li AH, Phanuphak N, Sahasrabuddhe VV, Chaithongwongwatthana S, Vermund SH, Jenkins CA, Shepherd BE, Teeratakulpisarn N, van der Lugt J, Avihingsanon A, **Ruxrungtham K**, Shikuma C, Phanuphak P, Ananworanich J. Anal squamous intraepithelial lesions among HIV positive and HIV negative men who have sex with men in Thailand. *Sex Transm Infect.* 2009 Dec;85(7):503-7.

16. Land S, Cunningham P, Zhou J, Frost K, Katzenstein D, Kantor R, Chen YM, Oka S, DeLong A, Sayer D, Smith J, Dax EM, Law M; TAQAS Laboratory Network. TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. *J Virol Methods.* 2009 Aug;159(2):185-93.

17. Mills AM, Nelson M, Jayaweera D, **Ruxrungtham K**, Cassetti I, Girard PM, Workman C, Dierynck I, Sekar V, Abeelee CV, Lavreys L. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. *AIDS.* 2009 Aug 24;23(13):1679-88.

18. van der Lugt J, Colbers A, Molto J, Hawkins D, van der Ende M, Vogel M, Wyen C, Schutz M, Koopmans P, **Ruxrungtham K**, Richter C, Burger D; SARA study team. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women. *Antivir Ther.* 2009;14(3):443-50.

19. Chang JJ, Sirivichayakul S, Avihingsanon A, Thompson AJ, Revill P, Iser D, Slavin J, Buranapraditkun S, Marks P, Matthews G, Cooper DA, Kent SJ, Cameron PU, Sasadeusz J, Desmond P, Locarnini S, Dore GJ, **Ruxrungtham K**, Lewin SR. Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. *J Virol.* 2009 Aug;83(15):7649-58.

20. van der Lugt J, Gorowara M, Avihingsanon A, Burger D, Ananworanich J, Sringam K, Kerr S, Wit F, Lange J, **Ruxrungtham K**. Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals. *AIDS*. 2009 Jun 1;23(9):1176-9.
21. Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likansakul S, Thawornwa U, Prommool V, **Ruxrungtham K**; N2R Study Team. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. *Clin Infect Dis*. 2009 Jun 15;48(12):1752-9.
22. Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, Puthanakit T, Mengthaisong T, Mahanontharit A, Lumbiganon P, Tompkins E, Burger D, **Ruxrungtham K**, Ananworanich J; HIV-NAT 017 Study Team. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. *Antivir Ther*. 2009;14(2):241-8.
23. Calmy A, Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, Burger F, Ubolyam S, Carr A, **Ruxrungtham K**, Hirschel B, Ananworanich J; STACCATO Study Group. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. *AIDS*. 2009 May 15;23(8):929-39.
24. Crane M, Oliver B, Matthews G, Avihingsanon A, Ubolyam S, Markovska V, Chang JJ, Dore GJ, Price P, Visvanathan K, French M, **Ruxrungtham K**, Lewin SR. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. *J Infect Dis*. 2009 Apr 1;199(7):974-81.
25. Walmsley S, Avihingsanon A, Slim J, Ward DJ, **Ruxrungtham K**, Brunetta J, Bredeek UF, Jayaweera D, Guittari CJ, Larson P, Schutz M, Raffi F. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. *J Acquir Immune Defic Syndr*. 2009 Apr 1;50(4):367-74.
26. Avihingsanon A, van der Lugt J, Kerr SJ, Gorowara M, Chanmano S, Ohata P, Lange J, Cooper DA, Phanuphak P, Burger DM, **Ruxrungtham K**. A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. *Clin Pharmacol Ther*. 2009; 85:402-8.
27. Ananworanich J, Puthanakit T, Saphonn V, Cooper DA, **Ruxrungtham K**. (2008). "Lessons from a multicentre paediatric HIV trial." *Lancet* 372(9636): 356-7.
28. Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, Marks P, Sasadeusz J, Cooper DA, Bowden S, Locarnini S, **Ruxrungtham K**, Dore GJ. A

randomized trial of combination hepatitis B therapy in HIV/HBV coinfecting antiretroviral naive individuals in Thailand. *Hepatology*. 2008

29. Ketloy C, Engering A, Srichairatanakul U, Limsalakpetch A, Yongvanitchit K, Pichyangkul S, **Ruxrungtham K**. Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates. *Vet Immunol Immunopathol*. 2008 May 8.

30. Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, Lumbiganon P, Burger D, **Ruxrungtham K**, Schutz M, Ananworanich J; HIV-NAT 017 Study Team. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. *Pediatr Infect Dis J* 2008;27:623-8. *Impact factor* 2.376

31. Ananworanich J, Nuesch R, Cote HC, Kerr SJ, Hill A, Jupimai T, Laopraynak N, Saenawat S, **Ruxrungtham K**, Hirschel B. Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy. *J Antimicrob Chemother* 2008;61:1340-3. *Impact factor* 4.038

32. van der Lugt J, Autar RS, Ubolyam S, Garcia EF, Sankote J, Avihingsanon A, Chuenyam T, Cooper DA, Lange J, Phanuphak P, Wit F, **Ruxrungtham K**, Burger D; HIV-NAT 019 Study Team. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naïve HIV-1-infected adults. *J Antimicrob Chemother* 2008;61:1145-53. *Impact factor* 4.038

33. Autar RS, Boyd MA, Wit FW, **Ruxrungtham K**, Sankote J, Lange J, Cooper DA, Phanuphak P, Burger DM, Reiss P. Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen. *Antivir Ther* 2007;12:1265-71. *Impact factor* 4.547

34. Manosuthi W, Sungkanuparph S, **Ruxrungtham K**, et al. Plasma Levels, Safety, and 60-Week Efficacy of a Once-Daily Double-Boosted Protease Inhibitor Regimen of Atazanavir, Saquinavir, and Ritonavir. *J Acquir Immune Defic Syndr*. 2008; 47:127-129.

35. Nuesch R, Ananworanich J, Srasuebkul P, Chetchotisakd P, Prasithsirikul W, Klinbuayam W, Mahanontharit A, Jupimai T, **Ruxrungtham K**, Hirschel B. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. *AIDS*. 2008; 22:152-4.

36. Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, **Ruxrungtham K**; Study Team. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir

+saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. *HIV Med.* 2007; 8:529-35.

37. Buranapraditkun S, Nookhai S, Ubolyam S, Sirivichayakul S, Phanuphak P, **Ruxrungtham K**. Cost savings by reagent reduction in flow cytometry-based CD4+ T cell counts: an approach to improve accessibility for HIV management. *Asian Pac J Allergy Immunol.* 2007; 25:83-9.

38. Boom J, Kösters E, Duncombe C, Kerr S, Hirschel B, **Ruxrungtham K**, de Mast Q, Kosalaraksa P, Ulbolyam S, Jupimai T, Ananworanich J; Staccato Study Group. Ferritin levels during structured treatment interruption of highly active antiretroviral therapy. *HIV Med.* 2007; 8):388-95.

39. Autar RS, Wit FW, Sankote J, Sutthichom D, Kimenai E, Hassink E, Hill A, Cooper DA, Phanuphak P, Lange JM, Burger DM, **Ruxrungtham K**. Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. *AIDS.* 2007 Jul 31;21(12):1535-9.

40. Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, **Ruxrungtham K**, Norris D, Lefebvre E, de Bethune MP, Tomaka F, De Pauw M, Vangeneugden T, Spinosa-Guzman S; TITAN study group. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. *Lancet.* 2007 Jul 7;370(9581):49-58

41. Wirach Maek-A-Nantawat, Supranee Buranapraditkun, Jettanong Klaewsongkram, **Kiat Ruxrungthum**. Increased Interleukin-17 Production Both in Helper T Cell Subset Th17 And CD4-Negative T Cells in Human Immunodeficiency Virus Infection. *Viral Immunology* 2007; 20:66-75.

42. Asasutjarit R, Lorenzen SI, Sirivichayakul S, **Ruxrungtham K**, Ruktanonchai U, Ritthidej GC. Effect of Solid Lipid Nanoparticles Formulation Compositions on Their Size, Zeta Potential and Potential for In Vitro pHIS-HIV-Hugag Transfection. *Pharm Res.* 2007 Mar 24.

43. Gayet-Ageron A, Ananworanich J, Jupimai T, Chetchotisakd P, Prasithsirikul W, Ubolyam S, Le Braz M, **Ruxrungtham K**, Rooney JF, Hirschel B. No change in calculated creatinine clearance after tenofovir initiation among Thai patients. *J Antimicrob Chemother.* 2007 Mar 21.

44. Hill A, **Ruxrungtham K**, Hanvanich M, Katlama C, Wolf E, Soriano V, Milinkovic A, Gatell J, Ribera E. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. *Expert Opin Pharmacother*. 2007 Apr;8(5):679-88.
45. Kerr SJ, Duncombe C, Avihingsanon A, Ananworanich J, Boyd M, Sopa B, Medtech B, Chuenyam T, Cooper DA, Lange JM, Phanuphak P, **Ruxrungtham K**. Dyslipidemia in an asian population after treatment for two years with protease inhibitor-containing regimens. *J Int Assoc Physicians AIDS Care (Chic Ill)*. 2007 Mar;6(1):36-46.
46. Kerr SJ, Duncombe C, Avihingsanon A, Ananworanich J, Boyd M, Sopa B, Medtech B, Chuenyam T, Cooper DA, Lange JM, Phanuphak P, **Ruxrungtham K**. Dyslipidemia in an asian population after treatment for two years with protease inhibitor-containing regimens. *J Int Assoc Physicians AIDS Care (Chic Ill)*. 2007 Mar;6(1):36-46.
47. Srasuebkul P, Ungsedhapand C, **Ruxrungtham K**, Boyd MA, Phanuphak P, Cooper DA, Law MG. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment. *HIV Med*. 2007 Jan;8(1):46-54.
48. Manosuthi W, **Ruxrungtham K**, Likansakul S, Prasithsirikul W, Inthong Y, Phoorisri T, Sungkanuparph S. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. *Clin Infect Dis*. 2007 Jan 1;44(1):141-4. Epub 2006 Nov 21.
49. Siripassorn K, Charoenwongse P, **Ruxrungtham K**. Three suitable antigens for delayed-type hypersensitivity skin testing in a tropical country like Thailand. *Asian Pac J Allergy Immunol*. 2006 Jun-Sep;24(2-3):143-52.
50. Chetchotisakd P, Anunnatsiri S, Kiertiburanakul S, Sutthent R, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Horsakulthai M, Chasombat S, **Ruxrungtham K**; Study Team. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant. *J Int Assoc Physicians AIDS Care (Chic Ill)*. 2006 Dec;5(4):152-6.
51. Avihingsanon A, Avihingsanon Y, Darnpornprasert P, Kerr S, Ungsedhapand C, Duncombe C, Ubolyam S, **Ruxrungtham K**, Phanuphak P. High prevalence of indinavir-associated renal complications in Thai HIV-infected patients. *J Med Assoc Thai*. 2006 Aug;89 Suppl 2:S21-7.
52. Boyd MA, Dixit NM, Siangphoe U, Buss NE, Salgo MP, Lange JM, Phanuphak P, Cooper DA, Perelson AS, **Ruxrungtham K**. Viral decay dynamics in HIV-infected patients

receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012). *J Infect Dis.* 2006 Nov 1;194(9):1319-22. Epub 2006 Sep 25.

53. Ananworanich J, Hirschel B, Sirivichayakul S, Ubolyam S, Jupimai T, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Schutz M, Snowden W, Ruxrungtham K; Staccato Study Team. Absence of resistance mutations in antiretroviral-naïve patients treated with ritonavir-boosted saquinavir. *Antivir Ther.* 2006;11(5):631-5.

54. Boyd MA, Carr A, **Ruxrungtham K**, Srasuebkul P, Bien D, Law M, Wangsuphachart S, Krisanachinda A, Lerdlum S, Lange JM, Phanuphak P, Cooper DA, Reiss P. Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. *J Infect Dis.* 2006 Sep 1;194(5):642-50.

55. Nuesch R, Srasuebkul P, Ananworanich J, **Ruxrungtham K**, Phanuphak P, Duncombe C; HIV-NAT Study Team. Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. *J Antimicrob Chemother.* 2006 Sep;58(3):637-44.

56. Ananworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Sirivichayakul S, Cavassini M, Karrer U, Genne D, Nuesch R, Vernazza P, Bernasconi E, Leduc D, Satchell C, Yerly S, Perrin L, Hill A, Perneger T, Phanuphak P, Furrer H, Cooper D, **Ruxrungtham K**, Hirschel B; Staccato Study Group; Swiss HIV Cohort Study. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. *Lancet.* 2006 Aug 5;368(9534):459-65.

57. Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W, Likanonsakul S, **Ruxrungtham K**. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. *Clin Infect Dis.* 2006 Jul 15;43(2):253-5.

58. Boyd MA, Srasuebkul P, Khongphattayanayothin M, **Ruxrungtham K**, Hassink EA, Duncombe CJ, Ubolyam S, Burger DM, Reiss P, Stek M Jr, Lange J, Cooper DA, Phanuphak P. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). *Antivir Ther.* 2006;11(2):223-32.

59. Boyd MA, Srasuebkul P, **Ruxrungtham K**, Mackenzie PI, Uchaipichat V, Stek M Jr, Lange JM, Phanuphak P, Cooper DA, Udomuksorn W, Miners JO. Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. *Pharmacogenet Genomics*. 2006 May;16(5):321-9.
60. Boyd MA, Siangphoe U, **Ruxrungtham K**, Reiss P, Mahanontharit A, Lange JM, Phanuphak P, Cooper DA, Burger DM. The use of pharmacokinetically-guided indinavir dose reductions in the management of indinavir-associated renal toxicity. *J Antimicrob Chemother*. 2006 Jun;57(6):1161-7.
61. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, **Ruxrungtham K**, Vibhagool A, Rattanasiri S, Thakkestian A. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. *AIDS*. 2006 Jan 2;20(1):131-2.
62. Autar RS, Wit FW, Sankote J, Mahanontharit A, Anekthananon T, Mootsikapun P, Sujaikaw K, Cooper DA, Lange JM, Phanuphak P, **Ruxrungtham K**, Burger DM. Nevirapine plasma concentrations and concomitant use of rifampin in patient coinfecting with HIV-1 and tuberculosis. *Antivir Ther*. 2005;10(8):937-43.
63. Boyd MA, Siangphoe U, **Ruxrungtham K**, Duncombe CJ, Stek M, Lange JM, Cooper DA, Phanuphak P. Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. *HIV Med*. 2005 Nov;6(6):410-20.
64. Ananworanich J, Kosalaraksa P, Hill A, Siangphoe U, Bergshoeff A, Pancharoen C, Engchanil C, **Ruxrungtham K**, Burger D; HIV-NAT 017 Study Team. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. *Pediatr Infect Dis J*. 2005 Oct;24(10):874-9.
65. Ananworanich J, Hill A, Siangphoe U, **Ruxrungtham K**, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Nuesch R, Cooper DA, Hirschel B; STACCATO Study Group. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naïve Thai patients. *Antivir Ther*. 2005;10(6):761-7.
66. Autar RS, Boffito M, Hassink E, Wit FW, Ananworanich J, Siangphoe U, Pozniak A, Cooper DA, Phanuphak P, Lange JM, **Ruxrungtham K**, Burger DM. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. *J Antimicrob Chemother*. 2005 Nov;56(5):908-13.

67. Manosuthi W, Sungkanuparph S, Thakkestian A, Vibhagool A, Kiertiburanakul S, Rattanasiri S, Prasithsirikul W, Sankote J, Mahanontharit A, **Ruxrungtham K**. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. *AIDS*. 2005 Sep 23;19(14):1481-6.
68. Ananworanich J, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, Mahanontharit A, Ubolyam S, Cooper D, Phanuphak P, **Ruxrungtham K**. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study. *J Acquir Immune Defic Syndr*. 2005 Aug 15;39(5):523-9.
69. Ananworanich J, Chantaphakul H, Teeratakulpisarn S, Siangphoe U, Ubolyam S, Chuenyam T, Ungsedhaphan C, Lange J, Cooper D, Phanuphak P, **Ruxrungtham K**. No effect of interleukin-2 on IgE levels given in addition to antiretroviral therapy in HIV-infected adults with CD4 >300 cells/mm³. *Asian Pac J Allergy Immunol*. 2005 Mar;23(1):23-8.
70. Boyd M, Mootsikapun P, Burger D, Chuenyam T, Ubolyam S, Mahanontharit A, Sangkote J, Bunyaprawit P, Horsakulchai M, Lange J, Cooper D, Phanuphak P, **Ruxrungtham K**. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. *Antivir Ther*. 2005;10(2):301-7.
71. Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, **Ruxrungtham K**, Lange J, Cooper D, Phanuphak P. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. *HIV Med*. 2005 Mar;6(2):122-8.
72. Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, **Ruxrungtham K**. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. *Clin Infect Dis*. 2005 Mar 1;40(5):728-34. Epub 2005 Feb 4.
73. Cardiello PG, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A, **Ruxrungtham K**, Hirschel B, Lange J, Phanuphak P, Cooper DA. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. *Clin Infect Dis*. 2005 Feb 15;40(4):594-600. Epub 2005 Jan 26.
74. Ananworanich J, Moor Z, Siangphoe U, Chan J, Cardiello P, Duncombe C, Phanuphak P, **Ruxrungtham K**, Lange J, Cooper DA. Incidence and risk factors for rash in Thai

patients randomized to regimens with nevirapine, efavirenz or both drugs. *AIDS*. 2005 Jan 28;19(2):185-92.

75. Duncombe C, Kerr SJ, **Ruxrungtham K**, Dore GJ, Law MG, Emery S, Lange JM, Phanuphak P, Cooper DA. HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting. *AIDS*. 2005 Jan 28;19(2):169-78.

76. Lolekha R, Sirivichayakul S, Siangphoe U, Pancharoen C, Kaewchana S, Apateerapong W, Mahanontharit A, Chotpitayasunondh T, **Ruxrungtham K**, Phanuphak P, Ananworanich J. Resistance to dual nucleoside reverse-transcriptase inhibitors in children infected with HIV clade A/E. *Clin Infect Dis*. 2005 Jan 15;40(2):309-12. Epub 2004 Dec 21.

77. Ananworanich J, Siangphoe U, Mahanontharit A, Hill A, Hirschel B, **Ruxrungtham K**. Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg. *Antivir Ther*. 2004;9:1035-6.

78. Ananworanich J, Pancharoen C, Sirivichayakul S, Buranapraditkun S, Apateerapong W, Ubolyam S, **Ruxrungtham K**. Undetectable plasma HIV-1 RNA with strong gag-pol specific interferon-gamma ELISPOT response in an HIV-1 clade A/E-infected child untreated with antiretroviral therapy. *Asian Pac J Allergy Immunol*. 2004;22:165-9.

79. Sirivichayakul S, Tirawatnpong T, **Ruxrungtham K**, Oelrichs R, Lorenzen SL, Xin KQ, Okuda K, Phanuphak P. Construction and immunogenicity study of a 297-bp humanized HIV V3 DNA of an approximated last common ancestor in mice. *Asian Pac J Allergy Immunol*. 2004;22:49-60.

80. Autar RS, Ananworanich J, Apateerapong W, Sankote J, Hill A, Hirschel B, Cooper D, Lange J, Phanuphak P, **Ruxrungtham K**, Burger D. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. *J Antimicrob Chemother*. 2004;54:785-90.

81. Ananworanich J, Cheunyam T, Teeratakulpisarn S, Boyd MA, **Ruxrungtham K**, Lange J, Cooper D, Phanuphak P. Creation of a drug fund for post-clinical trial access to antiretrovirals. *Lancet*. 2004 Jul 3;364(9428):101-2.

82. Chansritrakul S, Eiam-Ong S, Kansanabuch T, Wathanavaha A, **Ruxrungtham K**. Continuous ambulatory peritoneal dialysis improves both the number and memory function of CD4 T cells in uremic patients. *J Med Assoc Thai*. 2004 Apr;87(4):389-94.

83. Arduino RC, Nannini EC, Rodriguez-Barradas M, Schrader S, Losso M, **Ruxrungtham K**, Allende MC, Emery S, Fosdick L, Neaton J, Tavel JA, Davey RT, Lane HC; Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT) Vanguard Group; ESPRIT Executive Committee. CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies. Clin Infect Dis. 2004 Jul 1;39(1):115-22. Epub 2004 Jun 14.
84. Ungsedhapand C, Srasuebkul P, Cardiello P, **Ruxrungtham K**, Ratanasuwan W, Kroon ED, Tongtalung M, Juengprasert N, Ubolyam S, Siangphoe U, Emery S, Lange JM, Cooper DA, Phanuphak P; on Behalf of the HIV-NAT 002 and HIV-NAT 003 Study Team. Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection. J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):693-701.
85. Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, **Ruxrungtham K**, Lange JM, Phanuphak P, Cooper DA, Dore GJ. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS. 2004 May 21;18(8):1169-77.
86. van Leth F, Phanuphak P, **Ruxrungtham K**, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboledo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM; 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004 Apr 17;363(9417):1253-63.

งานวิจัยที่กำลังทำ

1. ผู้อำนวยการแผนงานวิจัย: การวิจัยโดยวิธีสุ่มที่ให้อาบบเปิดเผยเพื่อเปรียบเทียบความมีประสิทธิภาพของการเริ่มให้อาต้านไวรัสเมื่อซีดีสี่เท่ากับ 15 – 24 % หรือเริ่มให้อาต้านไวรัสเมื่อซีดีสี่ลดลงต่ำกว่า 15% ในเด็กที่ติดเชื้อเอชไอวีและมีภูมิคุ้มกันต่ำปานกลาง (PREDICT Study)

ระยะเวลา: ปี พ.ศ.2548-2552

แหล่งทุน: สถาบันวิจัยสุขภาพแห่งชาติ ประเทศสหรัฐอเมริกา

การวิจัยลุล่วงแล้วประมาณร้อยละ 50

2. ผู้อำนวยการแผนงานวิจัย: ผลของการเปรียบเทียบการให้อาต้านไวรัสแบบทันทีกับแบบรอในเด็กติดเชื้อเอชไอวีที่มีผลต่อการพัฒนาการทางระบบประสาท ในประเทศไทยและประเทศกัมพูชา

ระยะเวลา: ปี พ.ศ.2550-2552

แหล่งทุน: สถาบันสุขภาพจิตแห่งชาติ ประเทศสหรัฐอเมริกา

การวิจัยลุล่วงแล้วประมาณร้อยละ 50

3. ผู้อำนวยการแผนงานวิจัย: โครงการการใช้ยาต้านไวรัสเอชไอวีในผู้ติดเชื้อที่มีความล้มเหลวทางการรักษาจากยาสูตรแรกที่มีเอ็นเอ็นอาร์ทีไอ” (โครงการฮิฟสตาร์)
ระยะเวลา: ปี พ.ศ.2551-2553
แหล่งทุน: สำนักงานหลักประกันสุขภาพแห่งชาติ และสำนักงานคณะกรรมการวิจัยแห่งชาติ
การวิจัยลุล่วงแล้วประมาณร้อยละ 80
4. ผู้ร่วมวิจัย: Vaccine Research and Development in HIV/AIDS and Allergic Diseases
ระยะเวลา: ปี พ.ศ.2549-2552
แหล่งทุน: The Thai BIOTEC 5 years grant
การวิจัยลุล่วงแล้วประมาณร้อยละ 80
5. ผู้ร่วมวิจัย: DNA-based vaccine preclinical development for dengue
ระยะเวลา: ปี พ.ศ.2551-2552
แหล่งทุน: The Thai BIOTEC 5 years grant
การวิจัยลุล่วงแล้วประมาณร้อยละ 80

ประวัติคณะผู้วิจัยร่วม

ชื่อ-นามสกุล (ภาษาไทย): นายแพทย์ต่อศักดิ์ ปุณณบุรุต

ชื่อ-นามสกุล (ภาษาอังกฤษ): Torsak Bunupuradah (Mr.)

เลขหมายบัตรประจำตัวประชาชน: 3101702243463

ตำแหน่งปัจจุบัน: แพทย์วิจัยทางคลินิก และ กุมารแพทย์

หน่วยงานและสถานที่อยู่ติดต่อได้: ศูนย์ประสานความร่วมมือระหว่าง ไทย ออสเตรเลีย เนเธอร์แลนด์
เพื่อการศึกษาวิจัยทางคลินิกด้านโรคเอดส์ (HIV-NAT)

เลขที่ 104 ถนนราชดำริ เขตปทุมวัน กรุงเทพฯ 10330

โทรศัพท์: 02-6523040 Ext. 148 โทรสาร: 02-2525779 มือถือ: 089-890-5607

Email: torsak.b@hivnat.org

ประวัติการศึกษา

สถาบันการศึกษา	ระดับการศึกษา	ปีที่จบการศึกษา	สาขา
คณะแพทยศาสตร์ มหาวิทยาลัย เชียงใหม่	ปริญญาตรี ด้าน การแพทย์	2536-2541	ปริญญาบัตร แพทยศาสตรบัณฑิต
คณะแพทยศาสตร์ มหาวิทยาลัย เชียงใหม่	แพทย์ประจำบ้าน	2542-2545	กุมารแพทย์
ภาควิชาภูมิแพ้และภูมิคุ้มกัน หน่วยกุมารเวชศาสตร์ โรงพยาบาลรามธิบดี	แพทย์ใช้ทุน	2546-2548	ภูมิแพ้และภูมิคุ้มกัน

สาขาวิชาการที่มีความชำนาญพิเศษ: ภูมิแพ้ ภูมิคุ้มกัน และโรคเอดส์

ประสบการณ์ที่เกี่ยวข้องกับการบริหารงานวิจัยทั้งภายในและภายนอกประเทศงานวิจัยที่กำลังทำ

1. หัวหน้าโครงการ: ชื่อโครงการ HIV-NAT015 “Treatment outcome of children with HIV infection treated with highly active antiretroviral therapy” (N = 130)

แหล่งทุน: กระทรวงสาธารณสุข และ HIV-NAT

2. หัวหน้าโครงการ: ชื่อโครงการ PRENTA 11 Trial “Treatment Interruption in Children with Chronic HIV-Infection: the TICCH Trial To assess the safety of intermittent

แหล่งทุน: กระทรวงสาธารณสุข และ HIV-NAT

3. ART received according to CD4%, clinical disease progression, acute antiretroviral syndrome, change in ART regimen, toxicity, acceptability over 72 weeks.” (N=9)

แหล่งทุน: Paediatric European Network for Treatment of AIDS; PENTA

4. ผู้ร่วมงานวิจัย: PREDICT (Pediatric Randomized of Early vs Deferred Initiation in Cambodia and Thailand) “An open label, randomized study to compare antiretroviral therapy initiation in HIV infected children with moderate immune suppression”(N=300)
แหล่งทุน: The National Institutes of Health
5. ผู้ร่วมงานวิจัย: Neurodevelopment sub study of PREDICT “The effect of immediate versus deferred antiretroviral initiation on neurodevelopment in children with HIV in Cambodia and Thailand” (N=300)
แหล่งทุน: The National Institutes of Health
6. ผู้ร่วมงานวิจัย: HIV-NAT045 “ Kaletra low dose in HIV-infected children” (N=24)
แหล่งทุน: สำนักประสานและส่งเสริมกิจการอุดมศึกษา สำนักงานคณะกรรมการการอุดมศึกษา กระทรวงศึกษาธิการ, Global Fund
7. หัวหน้าโครงการ: MET-THAI “Motivation Enhance therapy (MET) in Thai HIV infected youth 16-24 Years”
แหล่งทุน: The National Institutes of Health
หัวหน้าโครงการ: HIV-NAT 077 “Kaletra mono maintenance therapy in HIV children” (N=40)
แหล่งทุน: สำนักประสานและส่งเสริมกิจการอุดมศึกษา สำนักงานคณะกรรมการการอุดมศึกษา กระทรวงศึกษาธิการ, Global Fund
8. หัวหน้าโครงการ: HIV STAR “The HIV Second-line Therapy AntiRetroviral study in patients who failed NNRTI-based regimens” LPV/r monotherapy VS LPV/r + 2NRTIs in adult patient who failed first line regimen (N=500)
หัวหน้าโครงการ: HIV-NAT 096 “A phase I/II study of Invirase boosted with Ritonavir in HIV infected children 4 months to 6 years old” (N=24)
แหล่งทุน: F. Hoffmann-La Roche Ltd.
9. ผู้ร่วมงานวิจัย: TREAT Asia’s Pediatric HIV Observational Database (TApHOD)
แหล่งทุน: amfAR

ผลงานวิจัยที่พิมพ์เผยแพร่

Posters presentation

1. A case report of x-linked hyperIgM syndrome (XHIM) with unusual fungal sinusitis, poster No. 74. **Torsak Bunupuradah**, Wiparat Manuyakorn, Wasu kamchaisatian Suwat Benjaponpitak. APAPARI – KAPARD Joint Congress 2005, April 7-9, 2005, Seoul, Korea.

2. A study using the In-check dial[®] to evaluate peak inspiratory flow rate from Thai children population age 5-18 years. **Bunupuradah T., MD**, Direkwattanachai C. American Academy of Allergy and Immunology (AAAAI) annual meeting 2006: poster presentation
3. Immune Recovery and Stopping Cotrimoxazole Prophylaxis in Thai patients Treated with NNRTI based HAART for 216 weeks. Chris Duncombe, Stephen Kerr, Chaiwat Ungsedhapand, Anchalee Avihingsanon, **Torsak Bunupuradah**, Wadchara Pumpradit, Kiat Ruxrungtham, David Cooper, Joep Lange, Praphan Phanuphak. CROI 2006.
4. Randomized Study of Immediate versus Deferred Highly Active Antiretroviral Therapy (HAART) in children. Ananworanich J, Kosalaraksa P, Pancharoen C, Engchanil C, Pornprasit P, Apateerapong W, Ubolyam S, Intasan J, Lumbiganond P, Phanuphak P and the HIV-NAT 010 Study Team (**Bunupuradah T** is part of the study group). CROI 2006.
5. Pharmacokinetics and 24 week Efficacy/Safety of Saquinavir/ Lopinavir/ Ritonavir in RTI Pre-treated Children, poster No. AP 0151. Jintanat Ananworanich, Pope Kosalaraksa, U. Siangphoe, A. Hill, Chitsanu Panchareon, C. Engchanil, J. Sankote, Jintana Intasan, Arpa Chuamchaitrakool, Theshinee Chuenyam, **Torsak Bunupuradah**, Praphan Phanuphak, David Burger, Kiat Ruxrungtham. The 10th National Seminar on HIV/AIDS, 13-15 July 2005, Bangkok, Thailand.
6. Efficacy and safety of double boosted saquinavir (SQV)/lopinavir/ritonavir (LPV/r) in nucleoside pre-treated children at 48 weeks, poster No. MOPE0201. Pope Kosalaraksa, **Torsak Bunupuradah**, Chulapan Engchanil, Pitch Boonrak, Jintana Intasan, Sasiwimol Ubolyam, Chitsanu Pancharoen, Pagakrong Lumbiganond, David Burger, Kiat Ruxrungtham, Malte Schutz, Jintanat Ananworanich, and the HIV-NAT 017 Study Team. AIDS 2006 - XVI International AIDS Conference, 13-18 August 2006 - Toronto, Canada.
7. Lack of PI resistance in children failing double boosted saquinavir (SQV)/lopinavir/ritonavir (LPV/r) combination, poster No. MOPE0202. **Torsak Bunupuradah**, Pope Kosalaraksa, Chulapan Engchanil, Sunee Sirivichayakul, Jintana Intasan, Sasiwimol Ubolyam, Chitsanu Pancharoen, Pagakrong Lumbiganond, Kiat Ruxrungtham, Malte Schutz, Jintanat Ananworanich, and the HIV-NAT 017 Study Team. AIDS 2006 - XVI International AIDS Conference, 13-18 August 2006 - Toronto, Canada.
8. Pharmacokinetic and virological evaluations after stopping NNRTIs in children: a substudy of the PENTA11 (TICCH) trial, poster No. MOPE0206. M Lallemand, D Burger, H Lyall and study group (**T Bunupuradah** is part of the PENTA 11 study group). AIDS 2006 - XVI International AIDS Conference, 13-18 August 2006 - Toronto, Canada.

9. Efficacy and safety of non nucleoside reverse transcriptase inhibitor (NNRTI) based highly active antiretroviral therapy (HAART) in Thai children with HIV, poster No. TUPEB128. **Bunupuradah T.**, Puthanakit T., Boonrak P., Butterworth O., Mengthaisong T., Intasan J., Ubolyam S., Kosalaraksa P., Engchanil C., Pancharoen C., Lumbiganond P., Phanuphak P., Ananworanich J., HIV-NAT Pediatric Study Team. 4th IAS conference, 22-25 July 2007, Sydney, Australia.
10. HIV disclosure in HIV positive Thai children, poster No.TUPEB142. Oratai Butterworth, Thanyawee Puthanakit, **Torsak Bunupuradah**, Tawan Mengthaisong, Waraporn Sakornjun, Jintanat Ananworanich ,Chitsanu Pancharoen, Jintana Intasan, Sangla Najai, Sasiwimol Ubolyam, Kiat Ruxrungham, and the HIV-NAT Pediatric Study Team. 4th IAS conference, 22-25 July 2007, Sydney, Australia.
11. Prevalence of anemia and impact of iron status in Thai and Cambodian HIV infected children with moderate immunosuppression (PREDICT study), poster No. TUPEB 137. Kosalaraksa P, Engchanil C, **Bunupuradah T**, Luesomboon W, Sunthornkachit R, Bunruen S, Intasan J, Jupimai T, Hirunwadee N, Lumbiganon P, Ruxrungham K on behalf of the PREDICT study team. 4th IAS conference, 22-25 July 2007, Sydney, Australia.
12. Immunological Recovery in Children starting NNRTI-based HAART in a resource limited setting, poster No. TUPEB 131. Puthanakit, T. Kerr, S.J. Ananworanich, J. **Bunupuradah, T.** Boonrak, P. Butterworth, O. Srisanthana, V. 4th IAS conference, 22-25 July 2007, Sydney, Australia.
13. Immune Reconstitution Inflammatory Syndrome, right sided hemiparesis, in a Thai HIV infected girl with severe immunosuppression. **Torsak Bunupuradah**, Thanyawee Puthanakit, Oratai Butterworth, Chitsanu Pancharoen, Jasper Van DerLugt, Praphan Phanuphak, Jintanat Ananworanich and the HIV-NAT Pediatric Study Team. World Allergy Congress 2-6 December 2007, Bangkok, Thailand.
14. Efficacy and safety of double boosted SQV/LPV/r combination at 96 weeks in Thai children who have failed NRTI/NNRTI-based regimens. **Torsak Bunupuradah**, Pope Kosalaraksa, Chulapan Engchanil, Pitch Boonrak, Tawan Hirunyanulux, Sasiwimol Ubolyam, Pagakrong Lumbiganon, Kiat Ruxrungham, Emily Labriola-Tompkins, Jintanat Ananworanich, and the HIV-NAT 017 Study Team. Poster number 586. The 15th Conference on Retroviruses and Opportunistic Infections 2008 (CROI 2008), Boston, USA.
15. Therapeutic Drug Monitoring of lopinavir and saquinavir in Thai HIV infected Children. Jasper van der Lugt, **Torsak Bunupuradah**, Pope Kosalaraksa, Thanyawee Puthanakit, Chulapan Engchanil, Waraporn Sakornjun, Meena Gorowara, Kiat Ruxrungham, David Burger, Jintanat Ananworanich and the HIV-

NAT 017 Study Team. Poster number 575. The 15th Conference on Retroviruses and Opportunistic Infections 2008 (CROI 2008), Boston, USA.

Publications

1. Use of taste-masking product, FLAVORx, to assist Thai children to ingest generic antiretrovirals. **Bunupuradah T**, Wannachai S, Chuamchaitrakool A, Intasan J, Nuchapong T, Neiss W, Kramm K, Pancharoen C, Burger D, Ananworanich J AIDS Research and Therapy, 2006, 3:30 (29 December 2006)
2. Regression of a cervical spinal mass following highly active antiretroviral therapy (HAART) in a child with advanced human immunodeficiency virus (HIV) disease. Lai Kim Leng, Chitsanu Pancharoen, **Torsak Bunupuradah**, Usa Thisyakorn, Panruethai Trinavarat, Darintr Sosothikul, Jintanat Ananworanich. Journal of Medical Association of Thailand, 2007 Sep; 90 (9):1937-42.
3. Double boosted protease inhibitors, saquinavir (SQV)/lopinavir/ritonavir (LPV/r), in nucleoside pre-treated children at 48 weeks. Pope Kosalaraksa, **Torsak Bunupuradah**, Chulapan Engchanil, Pitch Boonrak, Jintana Intasan, Pagakrong Lumbiganon, David Burger, Kiat Ruxrungtham, Malte Schutz, Jintanat Ananworanich, and the HIV-NAT 017 Study Team. The Pediatric Infectious Disease Journal, in press.

รางวัลที่เคยได้รับ

1. First prize of the Young Scientist Award 2006 from “A study using the In-check dial[®] to evaluate peak inspiratory flow rate from Thai children population age 5-18 years”, The 22nd National Congress on Allergy and Immunology 2006, Thai Allergy and Immunology Society, 31 Mar 2006, Bangkok, Thailand

อื่นๆ

The volunteer coordinator of 3 charities for HIV infected children and family at HIV-NAT, the Thai Red Cross AIDS Research Center since June 2005.

1. Born to Live charities with supported by Australian colleagues: www.borntolive.org
2. Art AIDS Fund (AAF) with supported by Netherlands colleagues: www.ArtAIDSfund.org
3. Living & Loving charity with supported by United Kingdom colleagues: www.LivingAndLoving.com

ชื่อ-นามสกุล (ภาษาไทย): เฟลินจันท์ เชษฐโชติศักดิ์

ชื่อ-นามสกุล (ภาษาอังกฤษ): Ploenchan Chetchotisakd

เลขหมายบัตรประจำตัวประชาชน: 3409900119682

ตำแหน่งปัจจุบัน: ศาสตราจารย์ ระดับ 11

หน่วยงานและสถานที่ติดต่อได้: ภาควิชาอายุรศาสตร์ คณะแพทยศาสตร์ มหาวิทยาลัยขอนแก่น

โทร. 043-363168

ประวัติการศึกษา

วุฒิปริญญาตรีความรู้ความชำนาญในการประกอบวิชาชีพเวชกรรม สาขาโรคติดเชื้อ	2542	แพทยสภา ประเทศไทย	วุฒิปริญญาตรีความรู้ความชำนาญในการประกอบวิชาชีพเวชกรรม สาขาโรคติดเชื้อ
Certificate of Clinical Fellowship Training in Infectious Disease	2536	Indiana University Medical Center, Indianapolis, Indiana, ประเทศสหรัฐอเมริกา	Certificate of Clinical Fellowship Training in Infectious Disease
วุฒิปริญญาตรีความรู้ความชำนาญในการประกอบวิชาชีพเวชกรรมสาขาอายุรศาสตร์	2531	คณะแพทยศาสตร์ โรงพยาบาลรามาธิบดี มหาวิทยาลัยมหิดล (แพทยสภา) ประเทศไทย	วุฒิปริญญาตรีความรู้ความชำนาญในการประกอบวิชาชีพเวชกรรมสาขาอายุรศาสตร์

สาขาวิชาการที่มีความชำนาญพิเศษ: โรคติดเชื้อ

ประสบการณ์ที่เกี่ยวข้องกับการบริหารงานวิจัยทั้งภายในและภายนอกประเทศงานวิจัยที่กำลังทำ

1. Principal investigator of maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with cotrimoxazole plus doxycycline.
2. Principal investigator of a randomized, double-blind, controlled study of cefoperazone/sulbactam plus co-trimoxazole Vs. ceftazidime plus co-trimoxazole in the treatment of severe melioidosis.
3. Principal investigator of a randomized, open-labeled, comparative trial of BID and TID dosing saquinavir oral enhancing formulation as part of triple therapy in advance AIDS patients.
4. Principal investigator of ESPRIT study at Srinagarind Hospital site: Evaluation of Subcutaneous Proleukin in a Randomized International Trial.
5. Principal investigator of STACCATO study at Srinagarind Hospital site: A randomized trial of CD4 guided treatment interruption, compared to continuous treatment, for HIV infection.

6. Principal investigator of antiretroviral treatment in HIV patients with NNRTI failure.
7. Principal investigator of a FG-463-21-08 at Srinagarind Hospital site: A randomized, comparative, double blind study of Micafungin (FK463) versus liposomal amphotericin B (Ambisome) in the treatment of invasive candidiasis and candidemia.
8. Principal investigator of BAMSG 3-01 study at Srinagarind Hospital site: A phase II randomized trial of amphotericin B alone or combination with fluconazole in the treatment of AIDS associated cryptococcal meningitis.
9. Principal investigator of TMC278-C204 study at Srinagarind Hospital site: A Phase IIb, randomized, partially blinded, dose-finding trial of TMC278 in anti-retroviral naïve HIV-1 infected subjects
10. Principal investigator of TMC114-C214 study at Srinagarind Hospital site: A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects.
11. Principal investigator of A Large Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (CPCRA065) or SMART at Srinagarind Hospital site.
12. Principal investigator of randomized placebo controlled trial of maintenance therapy of melioidosis with cotrimoxazole plus doxycycline compared with cotrimoxazole alone (MERTH study).
13. Principal investigator of TMC114-C211 study at Srinagarind Hospital site: A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-naïve HIV-1 infected subjects.
14. Principal investigator of AI424138 at Srinagarind Hospital site: A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment Naïve Subjects.
15. Principal investigator of an efficacy and safety of twice daily administration of cefepime in the empiric treatment of sepsis.
16. Principal investigator of WSA-CS-004 study at Srinagarind Hospital site: “A phase III, double blind, randomized study to evaluate safety and efficacy of BAL8557 versus voriconazole for primary treatment of invasive fungal disease caused by *Aspergillus* species or other filamentous fungi”.
17. Principal investigator of WSA-CS-008 at Srinagarind Hospital site: “A phase III, double blind, randomized study to evaluate safety and efficacy of BAL8557 versus caspofungin followed by voriconazole regimen in the treatment of candidemia and other invasive candida infections.”

18. Principal investigator of STALWART study at Srinagarind Hospital site: “Study of Aldesleukin and without Antiretroviral Therapy (ESPRIT 002: STALWART).”
19. Principal investigator of WSA-CS-003 at Srinagarind Hospital site: “Open label study of Isavuconazole in the treatment of patients with Aspergillosis and renal impairment or of patients with invasive fungal disease caused by rare moulds, yeasts or dimorphic fungi.”
20. Principal investigator of HIV STAR at Srinagarind Hospital site: “The HIV Second-line Therapy Antiretroviral study in patients who failed NNRTI-based regimens.”
21. Principal investigator of TMC 278 C209 at Srinagarind Hospital site: “A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve HIV-1 infected subjects”
22. Principal investigator of “Mycobacterial and Opportunistic Infections in HIV-Negative Thai Patients Associated with Autoantibodies to Interferon- γ ”
23. Principal investigator of DORIBAC 4003 at Srinagarind Hospital site: A post marketing surveillance study on the safety and effectiveness of Doripenem in the therapy of Thai patients with nosocomial pneumonia, complicated intra-abdominal infections and complicated urinary tract infections.
24. Principal investigator of START at Srinagarind Hospital site: Strategic Timing of AntiRetroviral Treatment.
25. Principal investigator of SECOND-LINE study at Srinagarind Hospital site: A randomised open - label study comparing the safety and efficacy of a ritonavir - boosted lopinavir and 2- 3N(t)RTI backbone versus ritonavir - boosted lopinavir and raltegravir in participants virologically failing firstline NNRTI/2N(t)RTI therapy.
26. Principal investigator of HPV-019 PRI at Srinagarind Hospital site: Safety and immunogenicity of Cervarix. in human immunodeficiency-virus infected females”.
27. Principal investigator of INSIGHT H1N1v Outpatient Study (FLU 002) at Srinagarind Hospital site: “An International Observational Study to Characterize Adults with Influenza A – Pandemic H1N1 (H1N1v).
28. Principal investigator of INSIGHT H1N1v Hospitalization Study (FLU 003) at Srinagarind Hospital site: An International Observational Study to Characterize Adults Who Are Hospitalized with Complications of Influenza A – Pandemic H1N1 (H1N1v).
29. Co-investigator of a study of EPV40001: A open-label, pilot study to explore the early antiretroviral activity and tolerability of abacavir and epivir when is administered once-daily within a triple combination regimen including abacavir, epivir and retrovir compared to the triple combination regimen administered twice-daily in antiretroviral naïve, HIV-1 infected subjects.

30. Co-investigator of a phase III prospective, randomized, multicenter, multinational study to compare the safety and efficacy of 4 mg/kg/day dose of NyotranTM versus 0.7 mg/kg/day of Fungizone (amphotericin B) in patients with cryptococcal meningitis.
31. Co-investigator of Risk factors for melioidosis and septicemic melioidosis.
32. Co-investigator of discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study.
33. Co-investigator of a randomized, open label comparative study of voriconazole versus conventional amphotericin B followed by fluconazole in the treatment of candidemia in non neutropenic subjects.
34. Co-investigator of a phase 3 randomized, double-blind, double-dummy non-inferiority study of the safety and efficacy of intravenous anidulafungin (VER002) vs oral fluconazole in the treatment of patients with esophageal candidiasis.
35. Co-investigator of a randomized, double-blind, controlled study of ceftazidime alone vs. ceftazidime plus co-trimoxazole in the treatment of severe melioidosis.

ผลงานวิจัยที่พิมพ์เผยแพร่

1. Boonma P, **Chetchotisakd P**. Interesting Infectious Disease Cases Presentation number 22: Fever, Diarrhea; Rash with Shock. J Infect Dis Antimicrob Agents 1989; 6:89-92.
2. Boonma P, Boonsawat W, Patjanasoonorn B. **Chetchotisakd P**, The Efficacy of Imipenem/Cilastatin in the Treatment of Melioidosis: A Preliminary Report from Srinagarind Hospital. J Infect Dis Antimicrob Agents 1990; 7:55-9.
3. **Chetchotisakd P**, Boonma P, Sookpranee M, et al. Rhinocerebral mucormycosis: A Report of 11 cases from Srinagarind Hospital. Southeast Asian J Trop Med Public Health. 1991; 22:268-73.
4. **Chetchotisakd P**, Pairojkul C, Porntaveevudhi O, *et al*. Human Pythiosis in Srinagarind Hospital: One year's experience. J Med Assoc Thai 1992; 75:248-54.
5. Patjanasoonorn B, Boonma P, Wilailackana C, Sittikesorn J, Lumbiganon P, **Chetchotisakd P**, Noppawinyoowong C, Aimajareuk K. Hospital acquired Janthinobacterium lividum septicemia in Srinagarind Hospital. J Med Assoc Thai 1992; 75 suppl 2: 6-10.
6. Jaroontum J, **Chetchotisakd P**, Khuntikeo N, Lumbiganon P, Kosuwon W, Manmontri W, Siripermphool P. Methicillin-resistant Staphylococcus aureus (MRSA) outbreaks in Srinagarind hospital. Srinagarind Med J 1994; 9:174-77.
7. **Chetchotisakd P**, Phelps C, Hartstein A. Assessment of Bacterial Cross-Transmission as a cause of Infections in Patients in Intensive Care Units. Clin Infect Dis 1994; 18: 929-37.

8. Buapoean J, Yurachai T, **Chetchotisakd P**, Hussaro D. Nosocomial Infection in Srinagarind hospital. *Srinagarind Med J* 1995; 10: 187-97.
9. Buapoean J, Hussaro D, **Chetchotisakd P**. Sharp wound injury and body fluid contact during work in Srinagarind hospital health personnel. *Srinagarind Med J* 1995; 10: 329-38.
10. Hartstein AI, **Chetchotisakd P**, Phelps CL, Lemonte AM. Typing of sequential bacterial isolates by Pulsed-field gel electrophoresis. *Diagn Microbiol Infect Dis* 1995; 22: 309-14.
11. Mootsikapun P, **Chetchotisakd P**. Cryptococcal meningitis in AIDS: clinical features and treatment related outcomes. *J Infect Dis Antimicrob Agents* 1995; 12: 103-9.
12. Mootsikapun P, **Chetchotisakd P**, Intarapoka B. *Pneumocystis carinii* pneumonia: clinical presentations, chest radiographs, and outcomes. *J Infect Dis Antimicrob Agents* 1996; 13: 83-8.
13. Mootsikapun P, **Chetchotisakd P**, Intarapoka B. Pulmonary infection in HIV infection patients. *J Med Assoc Thai* 1996; 79: 477- 85.
14. Tamprajamchit S, **Chetchotisakd P**, Thinkhamrop B. Cefoperazone/sulbactam + Co-trimoxazole vs ceftazidime + Co-trimoxazole in the treatment of severe melioidosis: a randomized, double-blind, controlled study. *J Med Assoc Thai* 1998; 81:265-71.
15. Choonhakarn C, **Chetchotisakd P**, Jirattananapochai K, Mootsikapun P. Sweet's syndrome associated with non-tuberculous mycobacterial infection: a report of five cases. *Bri J Dermatol* 1998; 139:107-10.
16. Anunnatsiri S, Chansung K, **Chetchotisakd P**, Sirijirachai C. Febrile neutropenia: a retrospective study in Srinagarind Hospital. *J Infect Dis Antimicrob Agents* 1998; 15:115-22.
17. Suwangool P, Suttinont C, Bowonwatanuwong C, Rajanuwong A, Kulpradist S, Dusitanond V, Chayakul P, **Chetchotisakd P**, Leelasupasri S, Aswapokee N. Efficacy and safety of twice daily administration of cefpirome in the empiric treatment of sepsis. *J Med Assoc Thai* 1999; 82:648-53.
18. Chayakul P, Sathapatayavongs B, **Chetchotisakd P**, Suwanagool P, Bowonwatanuwongs C, Vorachit M, Chongtrakool P. Evaluation of the efficacy and safety of teicoplanin in the treatment of gram positive infections. *J Infect Dis Antimicrob Agents* 1999; 16: 101-7.
19. Suputtamongkol Y, Chaowagul W, **Chetchotisakd P**, Lertpatanasuwun N, Intaranongpai S, Ruchutrakool T, Budhsarawong D, Mootsikapun P, Wuthiekanun V, Teerawatasook N, Lulitanond A. Risk factors for melioidosis and bacteremic melioidosis. *Clin Infect Dis* 1999; 29:408-13.
20. Charuchaimontri C, Suputtamongkol Y, Nilakul C, Chaowakul W, **Chetchotisakd P**, Lertpatanasuwan N, Intaranongpai S, Brett PJ, Wood DE. Antilipopolysaccharide II: an antibody protective against fatal melioidosis. *Clin Infect Dis* 1999; 29: 813-8.

21. **Chetchotisakd P**, Mootsikapun P, Anunnatsiri S, Jirattananapochai K, Choonhakarn C, Chaiprasert A, Na Ubol P, Wheat LJ, Davis TE. Disseminated infection due to rapidly growing mycobacteria in immunocompetent hosts presenting with chronic lymphadenopathy: a previously unrecognized clinical entity. Clin Infect Dis 2000; 30:29-34.
22. Reechaipichitkul W, Prathanee S, **Chetchotisakd P**, Kularbkaew C. Pulmonary melioidosis presenting with a lung mass undifferentiated from cancer. J Infect Dis Antimicrob Agents 2000; 17: 35-38.
23. Anunnatsiri S, **Chetchotisakd P**. Fever, jaundice with dyspnea in a patient with disseminated rapidly growing mycobacterial infection. J Infect Dis Antimicrob Agents 2000; 17: 83-6.
24. Wheat LJ, **Chetchotisakd P**, Williams B, Connelly P, Shutt K, Hajjeh R. Factors associated with severe manifestations of histoplasmosis in AIDS. Clin Infect Dis 2000; 30: 877-81.
25. Anunnatsiri S, **Chetchotisakd P**, Moostsikapun P, Auncharoen A. Pneumococcal infection and the trend in penicillin resistance at Srinagarind Hospital 1995 to 1999. J Infect Dis Antimicrob Agents 2000; 17:97-100.
26. Lumbiganon P, Tattawastra U, **Chetchotisakd P**, Wongratanacheewin S, Thinkhamrop B. Comparison between the antimicrobial susceptibility of *Burkholderia pseudomallei* to trimethoprim-sulfa-methoxazole by standard disk diffusion method and by minimal Inhibitory concentration determination. J Med Assoc Thai 2000; 83: 856-60.
27. **Chetchotisakd P**, Chaowagul W, Mootsikapun P, Budhsarawong D, Thinkamrop B. Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with cotrimoxazole plus doxycycline. Am J Trop Med Hyg 2001; 64: 24-7.
28. **Chetchotisakd P**, Porramatikul S, Mootsikapun P, Anunnatsiri S, Thinkhamrop B. Randomized, double-blind, controlled study of cefoperazone/sulbactam plus co-trimoxazole Vs. ceftazidime plus co-trimoxazole for the treatment of severe melioidosis. Clin Infect Dis 2001; 33: 29-34
29. **Chetchotisakd P**, Porramatikul S, Mootsikapun P, Anunnatsiri S, Thinkhamrop B. Reply: the role of cefoperazone-sulbactam for treatment of severe melioidosis. Clin Infect Dis 2002; 34: 722-3.
30. Pachirat O, **Chetchotisakd P**, Klungboonkrong V, Taweangsaksakul P, Tantisirin C, Loapiboon M. Infective endocarditis: prevalence, characteristics and mortality in Khon Kaen, 1990-1999. J Med Assoc Thai 2002; 85:1-10.
31. Pachirat O, Tasanavivat P, Klungboonkrong V, **Chetchotisakd P**, Tantisirin C, Limwattananon S, Taweangsaksakul P, Clinical outcome of native valve infective endocarditis in Khon Kaen:1990-1999. J Med Assoc Thai 2002; 85: 139-46.

32. **Chetchotisakd P**, Mootsikapun P, Anunnatsiri S, Boonyaprawit P, Wankun J. A randomized, open-labeled, comparative trial of BID and TID dosing of saquinavir enhanced oral formulation as part of a triple therapy for advance AIDS patients. *J Med Assoc Thai* 2002; 85: 590-6.
33. Vibhagool A, Sungkanuparph S, Mootsikapun P, **Chetchotisakd P**, Tansuphaswaswadikul S, Bowonwatanuwong C, Ingsathit A. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. *Clin Infect Dis* 2003; 36: 1329-31.
34. Mootsikapun P, **Chetchotisakd P**, Anunnatsiri S, Choksawadphinyo K. The efficacy of fluconazole 600 mg/day versus itraconazole 600 mg/day as consolidation therapy of cryptococcal meningitis in AIDS patients. *J Med Assoc Thai* 2003; 86: 293-8.
35. Sungkanuparph S, Vibhagool A, Mootsikapun P, **Chetchotisakd P**, Tansuphaswaswadikul S, Bowonwatanuwong C, Chantratita W. Efavirenz-based regimen as treatment of advanced AIDS with cryptococcal meningitis. *J Acquir Immune Defic Syndr* 2003; 33: 118-9.
36. Sungkanuparph S, Vibhagool A, Mootsikapun P, **Chetchotisakd P**, Tansuphaswaswadikul S, Bowonwatanuwong C. Opportunistic infections after initiation of highly active antiretroviral therapy in advanced AIDS patients in an area with high prevalence of tuberculosis. *AIDS* 2003; 17: 2129-31.
37. Ananworanich J, Nuesch R, Le Braz M, **Chetchotisakd P**, Vibhagool A, Wicharuk S, Ruxrungtham K, Furrer H, Cooper D, Hirschel B, and the Swiss HIV Cohort Study. Failure of 1 week on, 1 week off antiretroviral therapies in a randomized trial. *AIDS* 2003; 17: F33-37.
38. **Chetchotisakd P**, Sungkanuparph S, Thinkhamrop B, Mootsikapun P, Boonyaprawit P. A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. *HIV Medicine* 2004; 5: 140-3.
39. Anunnatsiri S, **Chetchotisakd P**, Wanke C. Factors associated with treatment outcomes in pulmonary tuberculosis in northeastern Thailand. *Southeast Asian J Trop Med Public Health* 2005; 36: 324-30.
40. Chierakul W, Anunnatsiri S, Short JM, Maharjan B, Mootsikapun P, Simpson AJ, Limmathurotsakul D, Cheng AC, Stepniewska K, Newton PN, Chaowagul W, White NJ, Peacock SJ, Day NP, **Chetchotisakd P**. Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis. *Clin Infect Dis* 2005; 41:1105-13.
41. Pachirat O, Kiatchoosakun S, **Chetchotisakd P**, Tantisirin C, Limwattananon S, Limwattananon J. Effect of changes in diagnosis and management of active infective endocarditis on the clinical outcome at Srinagarind Hospital. *J Med Assoc Thai* 2005; 88: 498-504.

42. Ananworanich J, Hill A, Ruxrungtham K, Siangphoe U, Prasithsirikul W, **Chetchotisakd P**, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Nuesch R, Cooper D A, Hirschel B, for the Staccato Study Group. A prospective cohort study of efficacy and safety of 2 NRTIs plus once-daily ritonavir-boosted saquinavir hard gel capsule (SQV-HGC/r) at 24 weeks. *Antiviral Therapy* 2005; 10: 761-7.
43. Ludy MJ, Hendricks K, Houser R, **Chetchotisakd P**, Mootsikapun P, Anunnatsiri. S, Price E, Wanke CA. Body composition of adults infected with human immunodeficiency virus in Khon Kaen, Thailand. *Am J Trop Med Hyg* 2005; 73:815-9.
44. Mootsikapun P, **Chetchotisakd P**, Anunnatsiri. S, Boonyaprawit P. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naïve HIV-1-infected patients with CD4 T cell counts < 200 cells/mm³: 96-week outcomes. *Antiviral Therapy* 2005;10: 911-6.
45. Ananworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, **Chetchotisakd P**, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Sirivichayakul S, Cavassini M, Karrer U, Genne D, Nuesch R, Vernazza P, Bernasconi E, Leduc D, Satchell C, Yerly S, Perrin L, Hill A, Perneger T, Phanuphak P, Furrer H, Cooper D, Ruxrungtham K, Hirschel B, the Staccato Group, the Swiss HIV Cohort Study. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomized trial. *Lancet* 2006; 368: 459-68.
46. Krajaejun T, Sathapatayavongs B, Prachartam R, Nitiyanant P, Leelachaikul P, Wanachiwanawin W, Chaiprasert A, Assanasen P, Saipetch M, Mootsikapun P, **Chetchotisakd P**, Lekhakula A, Mitarnun W, Kalnauwakul S, Supparatpinyo K, Chaiwarith R, Chiewchanvit S, Tananuvat N, Srisiri S, Suankratay C, Kulwichit W, Wongsaisuwan M, Somkaew S. Clinical and epidemiological analyses of human pythiosis in Thailand. *Clin Infect Dis* 2006; 43: 569-76.
47. Ananworanich J, Hirschel B, Sirivichayakul S, Ubolyam S, Jupimai T, Prasithsirikul W, **Chetchotisakd P**, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Schuta M, Snowden W, Ruxrungtham K; the Staccato Study Team. Absence of resistance mutations in antiretroviral-naïve patients treated with ritonavir-boosted saquinavir. *Antiviral Therapy* 2006;11: 631-5.
48. Foocharoen C, Mahakkanukrauh A, Foocharoen T, Suwannaroj S, **Chetchotisakd P**, Nanagara R. *Burkholderia pseudomallei* and mycobacterium co-existing infection in septic monoarthritis: a case report. *Intern Med J Thai* 2006; 22: 52-5.

49. **Chetchotisakd P**, Anunnatsiri S, Kiertiburanakul S, Sutthent R, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Horsakulthai M, Chasombat S, Ruxrungtham K, and the study team. High Rate Multiple- Drug Resistances in HIV-infected Patients Failing Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)-Regimens in Thailand where subtype A/E is predominant. *J Int Assoc Physicians AIDS Care* 2006; 5: 152-6.
50. Gayet-Ageron A, Ananworanich J, Jupimai T, **Chetchotisakd P**, Prasithsirikul W, Ubolyam S, Le Braz M, Ruxrungtham K, Rooney J F, Hirschel B, the Staccato Study Group. No change in calculated creatinine clearance after tenofovir initiation among Thai patients, *J Antimicrob Chemother* 2007; 59:1034-7.
51. Kuse ER, **Chetchotisakd P**, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA, for the Micafungin Invasive Candidiasis Working Group. Micafungin versus Liposomal Amphotericin B for Candidemia and Invasive Candidiasis in a Phase III, Randomized Double-blind Trial. *Lancet* 2007; 369: 1519-27.
52. **Chetchotisakd P**, Kiertiburanakul S, Mootsikapun P, Assanasen S, Chaiwarith R, Anunnatsiri S. Disseminated nontuberculous mycobacterial infection in patients who are not HIV infected in Thailand. *Clin Infect Dis* 2007; 45: 421-7.
53. Chierakul W, Anunnatsiri S, Chaowagul W, Peacock SJ, **Chetchotisakd P**, Day NP. Addition of trimethoprim-sulfamethoxazole to ceftazidime during parenteral treatment of melioidosis is not associated with a long-term outcome benefit. *Clin Infect Dis* 2007; 45: 521-3.
54. **Chetchotisakd P**, Anunnatsiri S, Puapermpoonsiri S, Prariyachatgul C, Chumpol J. A rapidly fatal case of Panton-Valentine positive *Staphylococcus aureus* necrotizing pneumonia in HIV-infected patient transmitted from his wife. *Southeast Asian J Trop Med Public Health* 2007; 38: 690-4.
55. **Chetchotisakd P**, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Ruxrungtham K, and the study team. Efficacy and tolerability of double boosted protease inhibitors (lopinavir+ saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with non-nucleoside reverse transcriptase inhibitors. *HIV Medicine* 2007; 8: 529-35.
56. Nüesch R, Ananworanich J, Srasuebkul P, **Chetchotisakd P**, Prasithsirikul W, Klinbuayam W, Mahanontharit A, Jupimai T, Ruxrungtham K, Hirschel B. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. *AIDS* 2008; 22: 152-4.

57. Cheng AC, Chierakul W, Chaowagul W, **Chetchotisakd P**, Limmathurotsakul D, Dance DA, Peacock SJ, Currie BJ. Consensus Guidelines for Dosing of Amoxicillin-Clavulanate in Melioidosis. *Am J Trop Med Hyg* 2008; 78: 208-9.
58. Ananworanich J, Gayet-Ageron A, Ruxrungtham K, **Chetchotisakd P**, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Le Braz M, Jumpimai T, Ubolyam S, Schutz M, Hirschel B, the Staccato Thailand Study Group. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. *Antiviral Therapy* 2008; 13: 375-80.
59. Molina JM, Andrade-Villanueva J, Echevarria J, **Chetchotisakd P**, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Thiry A, McGrath D; CASTLE Study Team. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. *Lancet* 2008; 372: 646-55.
60. **Chetchotisakd P**, Anunnatsiri S. Low-dose, once-daily atazanavir/ritonavir (200/100): an effective treatment for HIV-infected patients in Thailand. *J Acquir Immune Defic Syndr* 2008; 49:230-1.
61. Anunnatsiri S, **Chetchotisakd P**, Kularbkeaw C. Mycotic aneurysm in Northeast Thailand: the importance of *Burkholderia pseudomallei* as a causative pathogen. *Clin Infect Dis* 2008; 47: 1436-9.
62. Sungkanuparph S, Anekthananon T, Hiransuthikul N, Bowonwatanuwong C, Supparatpinyo K, Mootsikapun P, **Chetchotisakd P**, Kiertiburanakul S, Tansuphaswadikul S, Buppanharun W, Manosuthi W, Techasathit W, Ratanasuwan W, Tantisiriwat W, Suwanagool S, Leechawengwongs M, Ruxrungtham K; Thai AIDS Society. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. *J Med Assoc Thai*. 2008; 91:1925-35
63. Anunnatsiri S, **Chetchotisakd P**, Mootsikapun P. Fungemia in non-HIV-infected patients: a five-year review. *Int J Infect Dis*. 2009; 13:90-6.
64. Tippayawat P, Saenwongsa W, Mahawantung J, Suwannasaen D, **Chetchotisakd P**, Limmathurotsakul D, Peacock SJ, Felgner PL, Atkins HS, Titball RW, Bancroft GJ, Lertmemongkolchai G. Phenotypic and Functional Characterization of Human Memory T Cell Responses to *Burkholderia pseudomallei*. *PLoS Negl Trop Dis* 2009; 3: e407. Epub 2009 Apr 7.

65. Pappas PG, **Chetchotisakd P**, Larsen RA, Manosuthi W, Morris MI, Anekthananon T, Sungkanuparph S, Supparatpinyo K, Nolen TL, Zimmer LO, Kendrick AS, Johnson P, Sobel JD, Filler SG. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. *Clin Infect Dis* 2009; 48: 1775-83.
66. Manosuthi W, Sungkanuparph S, Anekthananon T, Supparatpinyo K, Nolen TL, Zimmer LO, Pappas PG, Larsen RA, Filler SG, **Chetchotisakd P**; For the BAMSG 3-01 Study Team. Effect of high-dose fluconazole on QT interval in patients with human immunodeficiency virus (HIV)-associated cryptococcal meningitis. *Int J Antimicrob Agents*. 2009; 34: 494-6.
67. Sungkanuparph S, Filler SG, **Chetchotisakd P**, Pappas PG, Nolen TL, Manosuthi W, Anekthananon T, Morris MI, Supparatpinyo K, Kopetskie H, Kendrick AS, Johnson PC, Sobel JD, Larsen RA. Cryptococcal Immune Reconstitution Inflammatory Syndrome after Antiretroviral Therapy in AIDS Patients with Cryptococcal Meningitis: A Prospective Multicenter Study. *Clin Infect Dis* 2009; 49: 931-4.
68. **Chetchotisakd P**. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naïve patients. *Expert Rev Anti Infect Ther* 2009; 7: 801-5.
69. Nüesch R, Gayet-Ageron A, **Chetchotisakd P**, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Chautrakarn S, Ruxrungtham K, Hirschel B, Anaworanich J; the STACCATO study group. The Impact of Combination Antiretroviral Therapy and its Interruption on Anxiety, Stress, Depression and Quality of Life in Thai Patients. *Open AIDS J*. 2009 Sep 15; 3: 38-45.
70. Zimmer LO, Nolen TL, Pramanpol S, Wallace D, Walker ME, Pappas P, **Chetchotisakd P**. International collaboration between US and Thailand on a clinical trial of treatment for HIV-associated cryptococcal meningitis. *Contemp Clin Trials*. 2010; 31:34-43.
71. Manosuthi W, **Chetchotisakd P**, Nolen T, Wallace D, Sungkanuparph S, Anekthananon T, Supparatpinyo K, Pappas P, Larsen R, Filler S, Andes D; on behalf of the BAMSG 3-01 Study Team. Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV-associated cryptococcal meningitis-infected patients. *HIV Med* 2010; 11:276-81.
72. Molina JM, Andrade-Villanueva J, Echevarria J, **Chetchotisakd P**, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Wirtz V, Lataillade M, Absalon J, McGrath D; for the CASTLE Study Team. Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naïve HIV-1-Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study. *J Acquir Immune Defic Syndr*. 2010; 53: 323-32.

73. Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, Wongsuvan G, Chaisuksant S, **Chetchotisakd P**, Chaowagul W, Day NP, Peacock SJ. Increasing incidence of human melioidosis in Northeast Thailand. Am J Trop Med Hyg. 2010; 82:1113-7.

รางวัลที่เคยได้รับ

- 2001 First Prize Young investigator awards, Infectious Disease Association of Thailand
- 2002 Second Prize Young investigator awards, Infectious Disease Association of Thailand
- 2002 First Prize Clinical Research, Faculty of Medicine, Khon Kaen University
- 2002 Second Prize Clinical Research, Faculty of Medicine, Khon Kaen University
- 2003 Young investigator consolation awards, Infectious Disease Association of Thailand
- 2003 Present in Research Highlight, Royal College of Physician of Thailand
- 2004 Best Academic Alumna from Khon Kaen Medical Alumni Association
- 2007 Best Academic Alumna from Khon Kaen University Alumni Association
- 2008 Present in Research Highlight, Royal College of Physician of Thailand
- 2009 Highest citation article of the year, Khon Kaen University

ชื่อ-นามสกุล (ภาษาไทย): พญ. จุรีรัตน์ บวรวัฒนวงศ์
 ชื่อ-นามสกุล (ภาษาอังกฤษ): Chureeratana Bowonwatanuwong
เลขหมายบัตรประจำตัวประชาชน: 3209900163047
ตำแหน่งปัจจุบัน: ผู้เชี่ยวชาญพิเศษ
 หน่วยงานและสถานที่ติดต่อได้: โรงพยาบาลชลบุรี แผนกอายุรกรรม
 โทรศัพท์: 038 931101-2 โทรสาร: 038 274911 มือถือ: 081 3446180
 Email: C.bowon@gmail.com

ประวัติการศึกษา

สถาบันการศึกษา	ระดับการศึกษา	ปีที่จบการศึกษา	สาขา
คณะแพทยศาสตร์ โรงพยาบาล รามธิบดี มหาวิทยาลัยมหิดล	ปริญญาตรี ด้าน การแพทย์	2518	ปริญญาบัตร แพทยศาสตรบัณฑิต
คณะแพทยศาสตร์ จุฬาลงกรณ์ มหาวิทยาลัย	Thai Board of Internal Medicine	2524	อายุรกรรม
Toranomon Hospital, Tokyo, Japan (JCMT, Japanese Council of Medical Training)	Certificate of Chronic Respiratory Care and Pulmonary Medicine	2528	Certificate of Chronic Respiratory Care and Pulmonary Medicine
Wadsworth VA & Cedars Sinai Medical Centers-UCLA Affiliated Hospitals, Los Angeles, CA USA (China Medical Board Foundation)	Visiting Physician MICU	2531	Wadsworth VA & Cedars Sinai Medical Centers- UCLA Affiliated Hospitals, Los Angeles, CA USA (China Medical Board Foundation)

สาขาวิชาการที่มีความชำนาญพิเศษ: โรคติดเชื้อ โรคทางเดินระบบหายใจ

ประสบการณ์ที่เกี่ยวข้องกับการบริหารงานวิจัยทั้งภายในและภายนอกประเทศงานวิจัยที่กำลังทำ

1. Academic committee on Antiretroviral therapy of Ministry of Public Health (MOPH)
2. Investigator, The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
3. Investigator, Program on HIV Prevention and Treatment (PHPT)
4. Principal Investigator, The study “Centers of excellence on HAART in Thailand”
5. HIV clinic starter and consultant, Queen Sirikit Hospital, Brurapha University Hospital, Rayong Hospital
6. HEARTT 2000 (Help, ensure, AIDS, rescue together in Thailand)
7. Senior advisor, Sang Song Jai Club (HIV/AIDS patients club in Chonburi)
8. Committee, Antiretroviral therapy in adult. National Health Security Office 2007-03-09
9. คณะทำงานด้านการรักษาพยาบาลผู้ติดเชื้อเอชไอวี/ผู้ป่วยเอดส์กรณีผู้ใหญ่ สำนักงานหลักประกันสุขภาพแห่งชาติ
10. Reviewer Journal AIDS Patient Care and STD
11. คณะอนุกรรมการและคณะทำงานเพื่อดำเนินการตามนโยบายการดูแลรักษาผู้ป่วยวัณโรค สำนักงานหลักประกันสุขภาพแห่งชาติ
12. คณะอนุกรรมการให้ความคุ้มครองแก่ผู้ประกันตนที่ติดเชื้อ HIV/ ผู้ป่วยเอดส์ สำนักงานประกันสังคม
13. แพทย์ผู้เชี่ยวชาญของคณะทำงานตรวจสอบข้อเท็จจริงเพื่อรับเงินช่วยเหลือตามมาตรา 41
14. Senior Investigator โครงการ RV 152 , Center Disease Control , MOPH
15. คณะทำงานกำกับทิศทางและติดตามการประเมินผลการดำเนินงานโครงการพัฒนาคุณภาพบริการดูแลผู้ติดเชื้อเอชไอวีและเอดส์ในระบบประกันสุขภาพถ้วนหน้า 2543
16. คณะกรรมการวิชาการด้านโรคติดเชื้อเอชไอวี/เอดส์ องค์การเภสัชกรรม
17. คณะทำงานพัฒนาองค์ความรู้การให้บริการยาต้านไวรัสสำหรับผู้ติดเชื้อเอชไอวีโดยผ่านกระบวนการเรียนรู้โรคโดยตรง กรมควบคุมโรค กระทรวงสาธารณสุข
18. คณะกรรมการบริหารราชวิทยาลัยอายุรแพทย์แห่งประเทศไทยวาระ 2551- 2555

ผลงานวิจัยที่พิมพ์เผยแพร่

1. Kessarin Chaisiri, **Chureeratana Bowowatanuwong**, Narat Kasettrat, Sasisopin Kietiburanakul. Oncidence of Tenofovir-associated Nephrotoxicity HIV-infected Patients at Chonburi Hospital. Chonburi Hospital Journal Vol 35 Jan-April 2010, p 3-10
2. **จรัสรัตน์ บวรวัฒนวงศ์** HIV/AIDS: From practice to Podium โรคเรื้อรังทางอายุรกรรม ๒ การประชุมวิชาการ Internal Medicine Day โรงพยาบาลขอนแก่น 2553 p. 46-56
3. Kessirin Chaisiri, **Chureeratana Bowonwatanuwong**, Pinyo Visuutimak, Jirachai Waiwarawooth, Narat Kaseettrat, Sasisopin Kiertburanakul. Incidence and risk factors of Tonofovir-Associayed Renal Function Decline among Thai HIV-infecte Patients with Low-Body Weight. Abstract Book. 26th. Annual meeting The Royal College of Physicians of Thailand 28 Apr-May 2, 2010 p. 87

4. **Chureeratana Bowonwatanuwong**. AIDS2010: from Reality to Research. Thai Journal of Pharmacology vol 32 No.1, 2010 p. 23
5. Mangala PH Jayathunge, **Chureeratana Bowonwatanuwong**, Wirach Maek-a-nantawat, Benjalak Phonrat and Punnee Pitisuttithum. Psychological burden of Abnormal PAP Smears among HIV-infected Women at Chon Buri Hospital, Thailand. 2010The Southeast Asian Journal of Tropical Medicine and Public Health Vol 41, No. 1 Jan 2010 p.224-234
6. Darin Areechokchai, **Chureeratana Bowonwatanuwong**, Benjaluck Phonrat, Punnee Pitisuttithum, and Wirach Maek-a-Nantawat. Pregnancy Outcomes Among HIV-Infected Women Undergoing Antiretroviral Therapy. The Open AIDS Journal, 2009, 3, 8-13
7. สมศักดิ์ อรรถศิลป์, **จรัสรัตน์ บวรวัฒนวงศ์**, นาฏพฐ์ สงวนวงศ์, ยุทธิชัย เกษตรเจริญ, ศรีประพา เนตรนิยม แนวปฏิบัติการผสมผสานวัณโรคและโรคเอดส์ สำนักวัณโรค กรมควบคุมโรค กระทรวงสาธารณสุข 2552
8. Mangalasiri Jayathunge, Punnee Pitisuttithum, **Chureeratana Bowonwatanuwong**, Wirach Maek-a-nantawat, benjaluck Phonrat. Abnormal PAP Smear and psychosocial burden of abnormal PAP smear on HIV infected women in Chonburi Hospital, Chonburi, Thailand
9. *S.Rerks-Ngarm*, J.Kim, R.Paris, **C. Bowonwatanuwong**, S. Nittayaphan, J.Kaewkungwal "Preliminary result of the extended evaluation of the virologic, immunologic, and clinical course of volunteers became HIV-1 infected during participation in a phase III vaccine trial (protocol RV152). Int Confe .AIDS. 2008 Aug.3-8; Abstract .Wepe 0287
10. **Chureeratana Bowonwatanuwong**. HIV/AIDS : Long term Treatment . เวชศาสตร์ร่วมสมัย Leadership in Medicine, Proceeding in 49th Annual Meeting, Faculty of Medicine, Chulalongkorn University 23-27 Jun, 2008 p. 167-172
11. Manosuthi W, Sungkanuparp S, Ruxrungtham K, Prasithsirikul W, Athichathanabadi C, Chaovavanich A, Tantisiriwat W, **Bowownwatanuwong C**, Chumpathat N., Chaovavanich Plasma levels, safety, and 60-week Efficacy of a Once-daily Double-Boosted ProteaseInhibitor Regimen of Atazanavir, Saquinavir, and Ritonavir. JAID Vol 47(1)1 January 2008pp.127-9
- 12.. Theerathummakorn C, Soontharos S, **Bowonwatanuwong C** .Comparison of the Effectiveness and Adverse Drug Reactions of NNRTI-based and PI-based Regimens Therapy among AIDS-patients at Chonburi Hospital, A Retrospective Descriptive Study. Chonburi Hospital Journal Vo. 32 No.3 September – December 2007 p.201-206

13. P. Chetchotisakd, S Anunnatsiri, P Moosikapun, S. Kiertiburakul, T Anekthananon, C. Bowowatanuwong, B Kowadisaiburana, K Supparatpinyo, K Ruxrungtham and the study team. Efficacy and tolerability of a double boosted protease inhibitors (lopinavir+saquinavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitor. HIV Medicine (2007) ,8, 529-535
14. Predictors of CD4 count changeover 8 months of follow up in HIV-1-infected patients with a CD4 count > 300 cells/uL who were assigned to 7.5 MIU interleukin-2. The ESPRIT research Group HIV Medicine (2007), 8, 112-123
15. Manosuthi W, Chaovavanich A, Prasithsirikul W, Athichathanabadi C, Likannonsakul S, Tantisiriwat W, **Bowonwatanuwong C**, Chumpathat N., Termvises P., Sungkanuparps S. Once-daily Double-boosted Protease Inhibitor regimen of Atazanavir, Saquinavir, and Ritonavir: 60 week efficacy and metabolic effect. Abstract 4th. IAS Conference on HIV Pathogenesis, treatment and prevention 22-25 Jul, 2007
16. Jourdain G., Briand N., Fregonese F, Halue G., Chutanunta A., Nilmanat A., Prommas S., **Bowonwatanuwong C.** Yuthavisuthi P., Lallemand M. Program for HIV Prevention and Treatment (PHPT)-IRD174 24 Month outcome of Nevirapine Based Highly Active Antiretroviral Therapy (HAART) in Women During the Postpartum Period: A PMTCT + Pilot Program Supported by the Global Fund in Thailand. Int Confe .AIDS. 2006 Aug 13-18;16 Abstract No.WeAb0102
17. TR Cressey, G Jourdain, P Kantiphong, **C.Bowowatanuwong**, F Fregonese et al Plasma drug level assessment of low doses of Saquinavir as part of a dual protease inhibitor regimen of saquinavir plus indinavir boosted with zidovudine in HIV infected patients in Thailand. 7th International Workshop on Clinical Pharmacology of HIV Therapy
18. Ioenchan Chetchotisakd, Siriluck Anunnatsiri, Sasisopin Kietburanakul, Ruengpung Sutthent, Thanomsak Anekthananon, **Chureeratana Bowonwatanuwong**, Boonchai Kowadisaiburana, Kuanchai Supparatpinyo, Manassinee Horakulthai, Sanchai Chasombat, Kiat Ruxrungtham and the study team. High Rate Multiple Drug Resistances in HIV- Infected Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Regimens in Thailand, Where Subtype A/E is Predominant Int Assoc Physicians AIDS Care 5(4);2006 Dec2006
19. Wiyada Hluangdansakul, Pitcha Phinchantra, **Chureeratana Bowonwatanuwong**. Prevalence of SIL and SCCA in Human Immunodeficiency Virus- Seropositive Women at Anonymous Clinic in Chonburi Hospital. J Med Assoc Thai Vol 89 No.3 2006 p. 289- 293

20. **C.Bowonwatanuwong**, P Seur and J Waiwaravut. Improvement in Lipoatrophy Following Switching from Stavudine to Didanosine : 48 week follow-up Antiviral Therapy 2005; 10:L26
21. **C Bowonwatanuwong**, L Warren, M Mosteller, S Haneline, A Handley, P Champreeda, C Brothers, W Spreen, A Hughes, and J Hernandez. Association of HLA-B*5701 and Hypersensitivity to Abacavir in a Sample of Thai Patients. Antiviral Therapy 2005, 10:L61
22. Cressey TR, Jourdain G, **Bowonwatanuwong C**, Fregonese F, Chutanunta A, Halue G, Buranawanitchakorn Y, Thongpaen S, Ngo-Giang-Huong N, Lallemand M. Preliminary data of a dual protease inhibitor regimen of nelfinavir plus indinavir boosted with ritonavir in HIV infected adult women in Thailand: efficacy, tolerability and plasma drug levels. 6th International Workshop on Clinical Pharmacology of HIV Therapy: 28-30 April 2005, Quebec, Canada. Abstract 7.2
23. Ei Ei Tin, Punnee Pitisuttithum, Varunee Desakorn, **Chureeratana Bowonwatanuwong**, Polrat Wilairatana, Srivicha Krudsood. The efficacy and adverse effects of GPO-vir (Stavudine+Lamivudine+Nevirapine) in treatment-naïve adult HIV patients. Southeast Asian J Trop Med Public Health. Vol.3 No.2 Mar.2005 p. 362-369
24. Wichmann O, Hongsiriwon S, **Bowonwatanuwong C**, Chotivanich K, Sukthana Y, Pukrittayakamee S. Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001 epidemic in Chonburi, Thailand. Tropical Medicine & International Health 2004 Sep;9(9):1022-9.
25. Gonzage Jourdain, Nichole Ngo-Giang-Huong, Sophie Le Coeur, **Chureeratana Bowonwatanuwong**, Pacharee Kantipong, Pranee Leechanachai, Surabhon Ariyadej, Prattana Leenasirimakul, Scott Hammer, Mark Lallemand for the Perinatal HIV Prevention Trial group. Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine- Based Antiretroviral Therapy. NEJMed Vol. 351:229-240, Jul 15, 2004
26. I.J. Collins, S. Le Coeur, G. Jourdain, **C.Bowonwatanuwong**, F. Fregonese, R. Klaijak, M. Lallemand. Maintaining benefits of Global Fund programs at the patients' level : The Urgent Need for the New Generic antiretrovirals (ARV) in Thailand. TuPeE5330 XV International AIDS Conference 2004, Bangkok 11-16 July 2004
27. Asda Vibhagool, Somnuek Sungkanuparh, Piroon Mootsikapun, Ploenchan Chetchotsak, Somsit Tansuphaswaswadikul, **Chureeratana Bowonwatanuwong**, And Atiporn Ingsathit. Discontinuation of Secondary Prophylaxis for Cryptococcal Meningitis in Human Immunodeficiency Virus-Infected Patients Treated with Highly Active Antiretroviral Therapy: A Prospective, Multicenter, Randomized Study. CID 2003;36(15May0 p.1329-1331

28. Tran TA, Bowonwatanuwong C, Kantipong P, Wongsarajana P, Nilmanat A, ChulanuntaA, Lallemant M, Jourdain G. Integrating HIV Medicine and Prevention Of Mother-to-Child transmission of HIV-1 in Thailand: PMTCT+ Ativir Ther. 2003;8(up.1):Abstract on. 1069
29. Vibhagool, S. Sunfkanuparph, P. Moosokapun, P.Chetchotisakd, S.Tansuphasawasdikul, **C.Bowonwatanuwong**, C. Rojanasirivej, J. Waiwrawut, W. Chantaratit. Discontinuation of Secondary prophylaxis for Cryptococcal Meningitis In HIV Infected Patients Treated with HAART: Prospective, Multi Center Randomized Study. Poster presentation TH PeB 7292 XIV International AIDS Conference 2002, Barcelona July 7-12.
30. S. Sunkanuparph, A. Vipagool, P. Moosikapaan, P. Chetchotesaktd, S.Tansuphasawasdiskul, **C. Bowonwatanuwong**, J. Waiwaravut, W. Chantaratit. Efavirenz based regimen in Advanced AIDS with cryptococcal meningitis: A Prospective. Poster presentation in Mon Pe B 3221. XIV International AIDS Conference 20002, Barcelona July 7-12.
31. **Bowonwatanuwong C**, Moosikapun P, Supparapinyo K ,et al. A randomised, opened lable study to investigate abacavir (ABC) and lamivudine (3TC) as once daily (QD) components of triple combination regimen (EPV4001). Oral presentation on of The 1st IAS Conference on HIV pathogenesis and treatment, July 8-11, 2001, Buenos Aires, Argentina. Abstract 4.
32. Suwangool P., Suttinont C., **Bowonwatanuwong C.**,Rajanu Wong A., Kulpradist SA, Dusitnanond V, Chayakul P, Chetchotisakd P, Leelasupasri S, Asawapokee N.. Efficacy and Safety of Twice Daily administration of Cefirome in the Empiric Treatment of Sepsis.. J Med. Assoc Thai. 1999 Jul,82(7):648-53
33. Chayakul P., Sathapatayawongs B, Chetchotisakd P, Suwangool P,**Bowonwatanuwong C.**, Chontrakool P. Evaluation of the Efficacy and Safety of teicoplanin in the Treatment of Severe Gram Postitive Infections. J Infect Dis Antimicrob Agents 1999,16():101-107
34. **Chureeratana Bowonwatanuwong**, Chirapa Punthawangkoon, Worawit Tunsiriwat. ARDS from Varicella Pneumonia in Healthy Host: A case Report. J Infec Dis. Antimicrob Agents.1997;14(1):31-33
35. **Chureeratana Bowonwatanuwong**, Worawit Tansiriwat, Chirapa Buntawangkoon. Suicidal Attempt by Lethal Dose Isoniazid and Rifampicin. Abstract in the 4th Congress of the Asian Pacific Society of Respirology, Oct 1996, p22.
36. **Bowonwatanuwong**. HIV Clinic in Chonburi Hospital : 1st. year report.The 22nd. Annual meeting of Infectious Disease Society of Thailand, 1996 Abstract

37. **Chureeratana Bowonwatanuwong**, Benjawan Sitthitrai, Suporn Palaruk, Tisawan Ampanpong. Acute Severe Asthma with Respiratory failure: 4 years Experience from Regional Hospital Surrounded by the Newly Developed Industrial Cities. Thai J Tuberc Chest Dis 1995;16(1):36-39
38. **C.Bowonwatanuwong**. Tuberculosis in Health Care Workers in Chonburi Hospital. The 21st Annual meeting of Infectious Disease Society of Thailand, 1995 Abstract
39. **Chureeratana Bowonwatanuwong**, Nuansri Chutimant. Chusak Kasemsan, Papis Sangiumpornpanich. Treatment of Invasive Pulmonary Aspergillosis with Fluconazole in an apparent Healthy Patient: A case Report. J Infect Dis Antimicro Agent 1995;12(3)133-5.
40. **C. Bowon**, W Tantraporn, P palaruk, T Ampanpong. Pulmonary Infection in Near Drowning with ARDS : The Difference Between Salt and Fresh Water Group. J Infect Dis Antimicrob Agents. 1994;11(2):61-63.
41. Kunihiro Yoshimura, **Chureeratana Bowonwatanuwong**, Naohiko Chonabayashi, Hiroichi Tanimoto. Contrecoup Pulmonary Contusion : A case report. Jikeikei Med. J 1994; 41 : 17-22
42. Paisan Kangvonkit, Pianchai Thearachote, Jarinda Thaisanganya, **Chureeratana Bowonwatanuwong**, Choosak Kasemsan, Narongsak Ocharoen. Ludwig's Angina Associated with Mediastinitis, Pleural empyema, and Pericarditis secondary from odontogenic infection : A case report. The Journal of oral and Maxillofacial Surgery Vol. 6 No.1 Jan-Jun 1994
43. **Chureeratana Bowonwatanuwong**, Prajej Ruankanchanasetr, Kaokamthong Tongyai. Treatment of Cryptococcal Meningitis in AIDS patients with Fluconazole: 3 Cases Experience. Abstract in the 8th. Annual Scientific Meeting of the Royal College on Internal Medicine of Thailand April, 1992.
44. Prajej Ruangkanchanasetr P., **Bowonwatanuwong C**, Thongyai K., Yothipitak P., Srikerd D. Treatment of Cryptococcal Meningitis in AIDS with Fluconazole " Experience in 2 cases" Journal of Infectious Diseases and Antimicrobial Agents. Vol 9 No 4 Oct-Dec 1992 p.179-183
45. **C. Bowon**, T. Ampanpong, K Tongyai ARDS in near Drowning: 7 year experience in Coastal City. Abstract in the sixth congress of the Western Pacific Association of Critical Care Medicine, Dec. 1-4, 1991, P.116.
46. **C. Bowon**, L. Luaprasert, N. Ratanakin. Alcoholic level in Serum and Saliva of Vehicle Accidental Victims in Emergency Room of Chonburi Regional Hospital. Abstract in the Third Scientific Meeting of the Ministry of Public Health. 12-14 Sep, 1990, p. 54.

47. **C. Bowonatanuwong**, S. Palaruk, T. Ampanpong, C. Sangiumpornpanich. Acute respiratory failure in falciparum Malaria. The 11th. Asia-Pacific congress on Diseases of the chest. November 19-22, 1989, Bangkok, Thailand.
Oral presentation # 194, abstract page.363
48. **Bowon**, Tongyai K Smoking Picture in Chonburi : Oral presentation and Proceedings in 6th World Conference on Smoking and Health. Otemachi, Tokyo 1987

Curriculum Vitae

Nr: OXF4001

site: 47

ประวัติส่วนตัว (Personal Data)

ชื่อ-สกุล (ภาษาไทย)	นพ. วิรัช กลิ่นบัวแย้ม		
Name (English)	Dr. Virat Klinbuayaem		
ตำแหน่ง (Position)	Internist	แผนก (Department)	Medicine
วัน/เดือน/ปี เกิด (Date of Birth)	18-Nov-60		
ที่อยู่ (Address)	275/21 ม. 4 ด. สันผักหวาน อ.หางดง เชียงใหม่ 50230		
	275/21 M.4 Sanpukwan, Hangdong, Chiangmai 50230		
โทรศัพท์ (Telephone)	0-5343-6104		
โทรสาร (Fax)	มือถือ (Mobile phone)	081-716-9184	Pager
E-mail address:	kggvirat@hotmail.com 0619923		
ใบประกอบโรคศิลป์เลขที่ (Medical License):	12505		
ความสามารถพิเศษ (Specialty-ies):			

ประวัติการศึกษา (Education)

สถาบันการศึกษา (INSTITUTION)	ระดับการศึกษา (DEGREE)	ปีจบการศึกษา (YEAR)	สาขา (FIELD OF STUDY)
Chiang Mai University	Bachelor	1985	Medicine
Chiang Mai University	Diploma	1993	Internal Medicine

ประวัติการทำงาน (Professional Experience)

ระยะเวลาการทำงาน จาก-ถึง (Period)	โรงพยาบาล (Hospital)	ตำแหน่ง (Title)	หน้าที่รับผิดชอบ (Responsibility)
2003-Present	Sankhampang Hospital	Internist	Medicine
2003	Chiang Mai Provincial Public Health Office	รางวัลผู้ดูแลผู้ป่วยเอดส์ดีเด่นยาวนาน	
1993-2003	Sanpatong Hospital	Deputy Director	รักษาการ, ดูแลผู้ป่วย

PHPT clinical trial participation

Project	Project title	Start date	Stop date	Role
GFATM	Global Fund	01-Sep-03	01-Jan-06	Investigator of Record
PHPT3	Monitoring HAART in HIV-infected patients in Thailand: Comparison of two strategies to monitor ARV treatment, based on CD4 cell count or viral load, to ensure optimal immunological and clinical outcome and preserve future treatment options in AIDS patients	17-Aug-05		Investigator of Record
COHORT	Observational cohort of HIV infected adults and children in the PHPT network hospitals in Thailand (COHORT)	06-Dec-06		Investigator of Record

Date วันที่

Page 1 of 4

Signature ลงชื่อ 

Curriculum Vitae

Nr: OXF4001

site: 47

Last Human Subject Protection Training


site	name	date train	diff
47	Virat Klinbuayaem	07-Oct-08	7.99

cv date: 29-Jul-08

Training details see next page

Date วันที่

Page 2 of 4

Signature ลงชื่อ .ร. 

Curriculum Vitae

Nr: OXF4001

site: 47


Virat Klinbuayaem

Training Records

Date	training title
26-Jan-06 to 27-Jan-06	PHPT 3 Co-investigator Meeting By Dr. Marc Lallemant, Dr. Federica Fregonese, Dr. Gonzague Jourdain, Prof. Supom Koetsawang, Suwalai Chalermpanmetagul, Praomsuda Sukrakanchana, Sangwan Saopaeng Place Eastin Hotel, Bangkok
23-Feb-06 to 23-Feb-06	Community Advisory Board (Sanpatong Hospital) By Sirirat Thammajitsakul, CAB Coordinator Place Sanpatong Hospital
28-Feb-06 to 02-Mar-06	HIV Diagnosis and Care in Children By Dr. Virat Klinbuayaem, Sirirat Thammajitsakul, Praomsuda Sukrakanchana, Suwalai Chalermpanmetagul, Dr. Suparat Kamchanavanit Place PHPT Office, Nakomping Hospital, Health Promotion Center
28-Mar-06 to 28-Mar-06	PHPT-Global Fund Cohort Co-Investigators Meeting By Dr. Gonzague Jourdain, Dr. Federica Fregonese, Ms. Intira Collins Place Amari Airport Hotel, Bangkok
28-Mar-06 to 28-Mar-06	PHPT-3 Co-Investigators Meeting By Dr. Gonzague Jourdain, Dr. Federica Fregonese, Mrs. Suwalai Chalermpanmetagul Place Amari Airport Hotel, Bangkok
23-Jun-06 to 23-Jun-06	PMTCT Plus National Co-investigators Meeting By TBA Place Amari Airport Hotel, Bangkok
24-Oct-06 to 26-Oct-06	International Symposium on Scaling up and Optimizing HIV Treatment and Care in Asia By Place Central Duang Tawan Hotel, Chiang Mai
03-Nov-06	Harvard University Human Subject Protection Training Program; version dated August 2006 By Viewed the presentation of the training program in human subject protection version dated August 2006 Place Self-training
08-Dec-06 to 08-Dec-06	PHPT-3 National Co-investigator Meeting By PHPT Place Eastin Bangkok Hotel, Bangkok
21-Jun-07 to 21-Jun-07	PHPT 5 National co Investigator Meeting By Pra-omsuda Sukrakanchana Place Amari Airport Hotel
03-Jul-07 to 03-Jul-07	GFATM National co-investigators meeting By Mrs. Pra-omsuda Sukrakanchana Place TK. Palace Hotel, Bangkok
04-Jul-07 to 06-Jul-07	National AIDS Seminar 11th By Thai MoPH officers Place Muang Thong Thani, Bangkok

Date วันที่

Page 3 of 4

Signature ลงชื่อ 

Curriculum Vitae

Nr: OXF4001

site: 47

06-Sep-07 to 06-Sep-07 Update guideline for ARV treatment in Thailand, National security health office
By Mrs.Suwalai Chalernpantmetagul
Place Sansai hospital / Oxfam 1 network meeting

16-Feb-08 to 19-Feb-08 Beyond access to antiretroviral therapy
By AMS-CMU
Place The Empress Hotel, Chiang Mai

19-Feb-08 to 19-Feb-08 Esther program, Thai-Laos collaboration
By Mrs.Suwalai Chalernpantmetagul
Place The Empress hotel, Chiang Mai

12-Mar-08 to 13-Mar-08 Data Analysis training
By PHPT
Place Department of Statistics, CMU

22-Apr-08 to 22-Apr-08 Bimonthly CAB meeting
By Ms.Sirirat Thammajitsagul
Place Sanpathong

09-Jun-08 to 09-Jun-08 PHPT-5 Co-investigator meeting
By Mrs.Pra-omsuda Sukrakanchana
Place Amari Airport hotel, Bangkok

03-Aug-08 to 08-Aug-08 AIDS Conference (AIDS 2008) in Mexico
By
Place Mexico City

07-Oct-08 Harvard University Human Subject Protection Training Program; version dated August 2006
By Viewed the presentation of the training program in human subject protection version dated August 2006
Place Self-training


10-Nov-08 to 21-Nov-08 HIV treatment/care and PMTCT
By Mrs.Suwalai Chalernpantmetagul
Place PHPT hospital network in Chiang Mai

24-Nov-08 to 26-Nov-08 Treating People with HIV: Research, Implementation Public Health. Symposium
By PHPT staffs
Place Chiang Mai Orchid Hotel, Chiang Mai

24-Feb-09 to 24-Feb-09 Meeting for preparation for the visit of the French Secretary of State for Foreign Affairs and Human Rights
By Mrs.Suwalai Chalernpantmetagul
Place Nakornping Hospital

Date วันที่

Page 4 of 4

Signature ลงชื่อ

CURRICULUM VITAE

Name: WISIT PRASITHSIRIKUL, MD.

PERSONAL DATA

Gender: Male
Date of birth: March 10, 1966
Citizenship: Thai
Marital status: Married
Office Address: Bamrasnaradura Infectious Diseases Institute
Tiwanon Rd., Nonthaburi 11000. Thailand
Tel. 0-2951-0481, 0-81811-5610
Fax 0-2590-3411

EDUCATIONS AND QUALIFICATIONS

1996-1998	Diplomate of Thai Board of Nephrology Master of Science King Chulalongkorn Memorial Hospital Chulalongkorn University, Bangkok, Thailand
1993-1996	Diplomate of Thai Board of Internal Medicine King Chulalongkorn Memorial Hospital Chulalongkorn University, Bangkok, Thailand
1993	Education Commission for Foreign Medical Graduates (ECFMG) Certification
1985-1991	Doctor of Medicine Faculty of Medicine, Prince of Songkhla University, Songkhla, Thailand

MEDICAL LICENSE

Since 1991	Medical License Number: 17374 (The Medical Council, Thailand)
------------	--

WORKS AND EXPERIENCES

1998-present	: Internist, Nephrologist, Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand
1996-1998	: Clinical Fellow in Nephrology, Nephrology Unit, King Chulalongkorn Memorial Hospital
1993-1996	: Resident in Internal Medicine, King Chulalongkorn Memorial Hospital
1992-1993	: General Practitioner, Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand
1991-1992	: Resident in Internal Medicine, Prince of Songkhla University Hospital

MEDICAL SOCIETIES

1990	Medical Council of Thailand Thai Medical Association
1996	The Royal College Physicians of Thailand
1997	The Medical Association of Thailand
1998	The Nephrology Society of Thailand
2001	Thai AIDS Society
2002	Thai Endocrine Society of Thailand

PUBLICATIONS

1. Kungsavivat P, Prasithsirikul W, Vanichcaroemol N. Splenic Abscess. Chula Journal of Internal Medicine 1994; 123-128.
2. Eiam-Ong S, Jongsithimahakul A, Prasithsirikul W, Normal Magnesium Homeostasis and Disorders. In Vichit Bunpagnavig (eds). Nephrology Textbook: Bangkok Publishing 1994: 252-267.
3. Prasithsirikul W, Chalapravat M. Apolipoproteins. Chula Journal of Internal Medicine 1996; 9 (12): 354-369.
4. Prasithsirikul W, Eiam-Ong S. Potential Roles of Tacrolimus (FK 506, Prograf). In: Renal Transplantation. The Journal of Nephrology Society of Thailand 1996; 2 (3); 227-235.
5. Prasithsirikul W, Eiam-Ong S. Non-invasive Investigation in Renal Osteodystrophy. The Journal of Nephrology Society of Thailand 1996; 2 (3); 275-286.
6. Sanapboon T, Prasithsirikul W, Eiam-Ong S. MDRD Study. The Journal of Nephrology Society of Thailand 1997; 3 (1); 47-57.

7. Prasithsirikul W, Eiam-Ong S. Tacrolimus (FK 506, Prograf). In Eiam-Ong S (eds). Organ Transplantation. Chulalongkorn University, Thai Red Cross Society 1997: 1263-78.
8. Prasithsirikul W, Eiam-Ong S. Bradykinin. In Eiam-Ong S (eds). Endothelium. Text and Journal Publication. 1997
9. Prasithsirikul W, Jongsithimahakul A, Chusil S. Hemoperfusion; in Eiam-Ong S (eds). Hemodialysis: Text and Journal Publication, 1999: 505-524.
10. Prasithsirikul W, Eiam-Ong S. Lipoproteins Metabolism in Dialytic Patients; in Eiam-Ong S (eds). Hemodialysis: Text and Journal Publication, 1999: 773-792.
11. Prasithsirikul W, Eiam-Ong S. Basic Knowledge of Bone in Renal Osteodystrophy; in Eiam-Ong S (eds). Hemodialysis: Text and Journal Publication, 1999: 793-805.
12. Chalermdamrichai P, Prasithsirikul W, Chotimavigit R, et al. Clinical Manifestations and Kidney Apperences in AIDS Patients with Proteinuria Over 1.5 gram/day. Communicable Disease Journal 1999; 25: 136-140.
13. Prasithsirikul W, Eiam-Ong S. Hypocalcemia and Hypercalcemia, in Eiam-Ong S (eds). Nephrology: Text and Journal Publication, 2000: 89-131.
14. Prasithsirikul W, HIV/AIDS and Kidney; in Eiam-Ong S (eds). Nephrology: Text and Journal Publication, 2000: 987-1001.
15. Prasithsirikul W, Renal Osteodystrophy, Dialysis-related Amyloidosis and Post Transplantation Bone Disease; in Eiam-Ong S (eds). Nephrology: Text and Journal Publication, 2000:1265-1278.
16. Prasithsirikul W, Jirasiritham S. Practical Problems of Hemodialysis Vascular Access. The Journal of Nephrology Society of Thailand 2001; 7 (2): 198 - 205.
17. Prasithsirikul W. Lopinavir/Ritonavir Virology. Thailand Medical Time CME Special 2002; 1 (13): 42 – 48.
18. Prasithsirikul W. Management of Abnormal Calcium, Phosphorus Homeostasis and Renal Osteodystrophy in End Stage Renal Disease. In Eiam-Ong S (eds). Practical Dialysis: Text and Journal Publication 2002: 879 – 893.
19. Prasithsirikul W, Bunnag P. Improvement of Fat Redistribution, Insulin Resistance and Hepatic Fatty Infiltration in HIV-Association Lipodystrophy Syndrome by Pioglitazone: A Case report. J Med Assoc Thai 2004; 87: 166 – 172.
20. Puttawong S, Prasithsirikul W, Vadcharavirad S. Prevalence of lipodystrophy in Thai – HIV infected patient s. J Med Assoc Thai 2004; 87 (6): 605 – 611.
21. Gold J, Batterham M, Prasithsirikul W, et al. Effects of Nandrolone Decanoate Compared with Placebo or Testosterone on HIV Associated Wasting: A Multi-Center, Randomized, Double-Blind Placebo Controlled Trial. HIV medicine 2004; 7 (3) : 146 – 155
22. Prasithsirikul W, Manosuthi W, Puttawong S. Antiretroviral drugs and the kidneys. Journal of Nephrology Society of Thailand 2004 ; 10 (2) : 178 - 199.

23. Lelavanichkul A, Eiam – ong S, Prasithsirikul W. Human Immune Deficiency Virus and Kidney. In : Nephrology. First edition. Editors : Eiam – ong S : Text and Journal Publication, 2004 : 1092 – 1134.
24. Prasithsirikul W. Renal Osteodystrophy : Calcium and Phosphorus Disturbances in Chronic Kidney Disease. In Eiam – ong S (eds). Nephrology : Text and Journal Publication, 2004 : 1372 – 1390.
25. Prasithsirikul W, Chirachanakul P. Severe Adverse Cutaneous Drugs Reactions in HIV Infected Patients at Bamrasnaradura Institute. Journal of Health Science 2005 ; 14 (4) : 607 – 613.
26. Prasithsirikul W, Dialysis and Renal Transplanttion in HIV Infected patients : case demonstation and review of the literature. Journal of nephrology Society of Thailand 2006 ; 12 (1) : 81 – 87.
27. Manosuthi W, Sungkanuparph S, Prasithsirikul W, et al. Efavirenz Levels and 24-Week Efficacy in HIV Infected Patients with Tuberculosis Receiving Highly Active Antiretroviral Therapy and Rifampin. AIDS 2005; 19: 1481 – 1486.
28. Ananworanich J, Hill A, Prasithsirikul W, et al. A Prospective Study of Efficacy and safety of Once Daily Saquinavir/Ritonavir Plus 2 NRTIs in Treatment Naïve Thai Patients. Antiviral Therapy 2005; 10: 761 – 7.
29. Manosuthi W, Sungkanuparph S, Prasithsirikul W, et al. Plasma Nevirapine Levels and 24-week Efficacy in HIV-Infected Patients Receiving-Based Highly Active Antiretroviral Therapy with or without Rifampin. Clinical Infectious Diseases 2006; 43: 253 – 5.
30. Ananworanich J, Angle Gayet-Ageron, Prasithsirikul W, et al. CD4-Guided Scheduled Treatment Interruptions Compared with Continuous Therapy for Patients Infected with HIV – 1: Results of the Staccato Randomised Trial. Lancet 2006; 368: 459 – 465.
31. Ananworanich J, Hirschel B, Prasithsirikul W, et al. Absence of Resistance Mutation in Antiretroviral-Naïve Patients Treated with Ritonavir-Boosted Saquinavir. Antiviral Therapy 2006; 11: 1- 5.

ชื่อ-นามสกุล (ภาษาไทย): พญ.สุพรรณิ จิรจรียาเวช
 ชื่อ-นามสกุล (ภาษาอังกฤษ): Dr.Supanee Jirajariyavej
 เลขหมายบัตรประจำตัวประชาชน: 3101202200544
 ตำแหน่งปัจจุบัน: นายแพทย์ 7 วช.
 หน่วยงานและสถานที่ติดต่อได้: โรงพยาบาลตากสิน
 ที่อยู่ 543 ถ.สมเด็จพระเจ้าพระยา เขตคลองสาน กรุงเทพฯ 10600
 โทรศัพท์: 02-437 0123-4 Ext. 1140 โทรสาร: 02-8631379 มือถือ: 081-3744264
 Email: jsupanee@yahoo.com

ประวัติการศึกษา

สถาบันการศึกษา	ระดับการศึกษา	ปีที่จบการศึกษา	สาขา
คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย	ปริญญาตรี ด้านการแพทย์	2546	ปริญญาบัตร แพทยศาสตร์บัณฑิต
คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย	แพทย์เฉพาะทาง	2550	โรคติดเชื้อ

สาขาวิชาการที่มีความชำนาญพิเศษ: โรคติดเชื้อ โรคเอดส์

ประสบการณ์ที่เกี่ยวข้องกับการบริหารงานวิจัยทั้งภายในและภายนอกประเทศงานวิจัยที่กำลังทำ

แพทย์ผู้เชี่ยวชาญด้านโรคติดเชื้อ โรงพยาบาลตากสิน

2005ประธานอนุกรรมการควบคุมโรคติดเชื้อโรงพยาบาลตากสิน

2006ประธานอนุกรรมการพัฒนาคุณภาพการดูแลผู้ป่วยติดเชื้อเอชไอวี/เอดส์

2007รองประธานอนุกรรมการ Drug use evaluation

2008ผู้ร่วมงานวิจัย: HIV STAR “The HIV Second-line Therapy AntiRetroviral study in patients who failed NNRTI-based regimens” LPV/r monotherapy VS LPV/r + 2NRTIs in adult patient who failed first line regimen

ผลงานวิจัยที่พิมพ์เผยแพร่

1. Ceftriaxone in female with acute pyelonephritis with ESBL producing
2. Outbreak of endophthalmitis in Thammasart

ชื่อ - นามสกุล (ภาษาไทย) : แพทย์หญิง วรางคณา มั่นสกุล
 ชื่อ - นามสกุล (ภาษาอังกฤษ) : Warangkana Munsakul (Mrs.)
 เลขหมายบัตรประจำตัวประชาชน : 3 5099 01328 012
 ตำแหน่งปัจจุบัน : นายแพทย์ 8 วช.
 หัวหน้าหน่วยโรคติดเชื้อ ภาควิชาอายุรศาสตร์
 หน่วยงานและสถานที่ติดต่อได้ : หน่วยโรคติดเชื้อ ภาควิชาอายุรศาสตร์
 วิทยาลัยแพทยศาสตร์กรุงเทพมหานครและวชิรพยาบาล
 681 ถนนสามเสน แขวงวชิระ เขตดุสิต กรุงเทพฯ 10300
 โทรศัพท์ : 02-2443491 โทรสาร : 02-2448021 มือถือ : 081-6225305
 Email : nateemun@yahoo.com

ประวัติการศึกษา

สถาบันการศึกษา	ระดับการศึกษา	ปีจบการศึกษา	สาขา
คณะแพทยศาสตร์ มหา วิทยาเชียงใหม่	ปริญญาตรี ด้าน การแพทย์	2526 - 2532	ปริญญาบัตร แพทยศาสตรบัณฑิต
คณะแพทยศาสตร์ มหา วิทยาเชียงใหม่	แพทย์ประจำบ้าน	2532 - 2536	อายุรแพทย์

13 ก.พ. 2546 อนุมัติบัตร อ.ว. (เวชศาสตร์ครอบครัว)
 10 มี.ค. 2548 อนุมัติบัตร อนุสาขอายุรศาสตร์ โรคติดเชื้อ

สาขาวิชาการที่มีความชำนาญพิเศษ : โรคติดเชื้อ อายุรศาสตร์เขตร้อน และโรคเอดส์

ประสบการณ์ที่เกี่ยวข้องกับการบริหารงานวิจัยทั้งภายในและภายนอกประเทศงานวิจัยที่กำลังทำ

1. การศึกษาเปรียบเทียบประสิทธิภาพและความปลอดภัยของยาอีโวฟลอกซาซิน (ขนาด 500 มิลลิกรัม วันละ 1 ครั้ง 7-14 วัน) กับยา ซิโปรฟลอกซาซิน ในการรักษาผู้ป่วยกรวยไตอักเสบเฉียบพลัน ที่เกิดจากการติดเชื้อในชุมชนทำในหลายสถาบัน
2. STACCATO – A Randomized Trial of Two Types of Treatment Interruption, Compared to Continuous Treatment, for HIV Infections.
3. โครงการ : HIV STAR “The HIV Second-line Therapy AntiRetroviral study in patients who failed NNRTI-based regimens” LPV/r monotherapy VS LPV/r + 2NRTIs in adult patient who failed first line regimen (N=500)

ผลงานวิจัยที่พิมพ์เผยแพร่

1. Penicillin Resistant Streptococcus Pneumoniae, Vajira Medical Journal, Vol. 46, No. 1, January 2002.
2. Effectiveness and Side Effects of Therapy Using a 3 – drug Antiretroviral Tablet : Nevirapine / Stavudine / Lamivudine (GPO vir) in HIV – infected Patients, Vajira Medical Journal, Vol. 47, No 1, January, 2003.
3. Asymptomatic Bacteriuria in Women with Type 2 Diabetes. Journal of Infectious Diseases and Antimicrobial Agents. Vol. 20, No 2, May – Aug 2003.
4. Pulmonary Rhodococcosis in AIDS Patients : Report of Two Cases in Bangkok Metropolitan Administration Medical College and Vajira Hospital. Journal of Infectious Diseases and Antimicrobial Agents, Vol.21, No.1, Jan – Apr 2004.